Immunomodulation mechanism of antidepressants: Interactions between serotonin/norepinephrine balance and Th1/Th2 balance

Current Neuropharmacology

Volumn 10, Issue 2, 2012, Pages 97-123

  Martino, Matteo ^a   Rocchi, Giulio ^a   Escelsior, Andrea ^a   Fornaro, Michele ^a,b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

Antidepressants; Cytokines; Neurotransmitters; Receptors; Th1; Th2

Indexed keywords

ACETYLCHOLINE; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ATOMOXETINE; CYTOKINE; DOPAMINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; GLUCOCORTICOID; HISTAMINE; IMIPRAMINE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEUROTRANSMITTER; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; PAROXETINE; PHENELZINE; REBOXETINE; SELEGILINE; SEROTONIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRIPLE REUPTAKE INHIBITOR; UNINDEXED DRUG; VENLAFAXINE;

ALLERGIC DISEASE; ANTIDEPRESSANT ACTIVITY; ANXIETY; AUTOIMMUNE DISEASE; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COGNITIVE DEFECT; COMORBIDITY; CORONARY ARTERY DISEASE; CROHN DISEASE; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DEPRESSION; DRUG EFFICACY; DRUG UPTAKE; HASHIMOTO DISEASE; HEART ARRHYTHMIA; HEART RATE; HUMAN; HYPOTHESIS; IMMUNOMODULATION; INFECTION; INFLAMMATORY DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; LOW DRUG DOSE; MENTAL DISEASE; METABOLIC DISORDER; NEOPLASM; NERVOUS SYSTEM INFLAMMATION; NEUROENDOCRINE SYSTEM; NEUROIMMUNOLOGY; NEUROTRANSMISSION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INTERACTION; PSORIASIS; RECEPTOR SENSITIVITY; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; TH1 CELL; TH2 CELL;

EID: 84861757593     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/157015912800604542     Document Type: Review

References (465)

1. Elenkov, I.J. Neurohormonal-cytokine interactions: implications for inflammation, common human diseases and well-being. Neurochem. Int., 2008, 52(1-2), 40-51.
2. Kidd, P. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern. Med. Rev., 2003, 8(3), 223-246.
3. Hickie, I.; Lloyd, A. Are cytokines associated with neuropsychiatric syndromes in humans? Int. J. Immunopharmacol., 1995, 17(8), 677-683.
4. Janssen, D.G.; Caniato, R.N.; Verster, J.C.; Baune, B.T. A psychoneuroimmunological review on cytokines involved in antidepressant treatment response. Hum. Psychopharmacol., 2010, 25(3), 201-215.
5. Halaris, A. Comorbidity between depression and cardiovascular disease. Int. Angiol., 2009, 28(2), 92-99.
6. Rabi-Zikic, T.; Zarkov, M.; Nedic, A.; Slankamenac, P.; Zivanovic, Z.; Dobrenov, D. Depression as the cause and consequence of cerebrovascular diseases. Med. Pregl., 2007, 60(5-6), 255-260.
7. Maunder, R.G.; Levenstein, S. The role of stress in the development and clinical course of inflammatory bowel disease: epidemiological evidence. Curr. Mol. Med., 2008, 8(4), 247-252.
8. Kurina, L.M.; Goldacre, M.J.; Yeates, D.; Gill, L.E. Depression and anxiety in people with inflammatory bowel disease. J. Epidemiol. Commun. Health, 2001, 55(10), 716-720.
9. Kurd, S.K.; Troxel, A.B.; Crits-Christoph, P.; Gelfand, J.M. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch. Dermatol., 2010, 146(8), 891-895.
10. Wilson, I. Depression in the patient with COPD. Int. J. Chron Obstruct. Pulmon. Dis., 2006, 1(1), 61-64.
11. Bruce, T.O. Comorbid depression in rheumatoid arthritis: pathophysiology and clinical implications. Curr. Psychiatry Rep, 2008, 10(3), 258-264.
12. Siegert, R.J.; Abernethy, D.A. Depression in multiple sclerosis: a review. J. Neurol. Neurosurg. Psychiatry, 2005, 76(4), 469-475.
13. Wekking, E.M. Psychiatric symptoms in systemic lupus erythematosus: an update. Psychosom. Med., 1993, 55(2), 219-228.
14. Egede, L.E.; Ellis, C. Diabetes and depression: global perspectives. Diabetes Res. Clin. Pract., 2010, 87(3), 302-312.
15. Bunevicius, R. Thyroid disorders in mental patients. Curr. Opin. Psychiatry, 2009, 22(4), 391-395.
16. Anisman, H.; Merali, Z.; Hayley, S. Neurotransmitter, peptide and cytokine processes in relation to depressive disorder: comorbidity between depression and neurodegenerative disorders. Prog. Neurobiol., 2008, 85(1), 1-74.
17. Yates, W.R.; Gleason, O. Hepatitis C and depression. Depress Anxiety, 1998, 7(4), 188-193.
18. Benton, T.D. Depression and HIV/AIDS. Curr. Psychiatry Rep., 2008, 10(3), 280-285.
19. Reich, M. [Depression in oncology]. Cancer Radiother., 2010, 14(6-7), 535-538.
20. Mosmann, T.R.; Coffman, R.L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol., 1989, 7, 145-173.
21. Sanders, V.M.; Baker, R.A.; Ramer-Quinn, D.S.; Kasprowicz, D.J.; Fuchs, B.A.; Street, N.E. Differential expression of the beta2-adrenergic receptor by Th1 and Th2 clones: implications for cytokine production and B cell help. J. Immunol., 1997, 158(9), 4200-4210.
22. Gonzalez, A.; Fazzino, F.; Castillo, M.; Mata, S.; Lima, L. Serotonin, 5-HT1A serotonin receptors and proliferation of lymphocytes in major depression patients. Neuroimmunomodulation, 2007, 14(1), 8-15.
23. Lima, L.; Urbina, M. Serotonin transporter modulation in blood lymphocytes from patients with major depression. Cell Mol. Neurobiol., 2002, 22(5-6), 797-804.
24. Sternberg, E.M. Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens. Nat. Rev. Immunol., 2006, 6(4), 318-328.
25. Farber, L.; Haus, U.; Spath, M.; Drechsler, S. Physiology and pathophysiology of the 5-HT3 receptor. Scand. J. Rheumatol. Suppl, 2004, 119, 2-8.
26. Mossner, R.; Lesch, K.P. Role of serotonin in the immune system and in neuroimmune interactions. Brain Behav. Immun., 1998, 12(4), 249-271.
27. Okuyama-Tamura, M.; Mikuni, M.; Kojima, I. Modulation of the human glucocorticoid receptor function by antidepressive compounds. Neurosci. Lett., 2003, 342(3), 206-210.
28. Paul, E.W. Fundamental Immunology. Lippincott Williams & Wilkins. Philadelphia. 2003.
29. de Kloet, E.R.; Derijk, R.H.; Meijer, O.C. Therapy Insight: is there an imbalanced response of mineralocorticoid and glucocorticoid receptors in depression? Nat. Clin. Pract. Endocrinol. Metab., 2007, 3(2), 168-179.
30. Rook, G.A. Glucocorticoids and immune function. Baillieres Best Pract. Res. Clin. Endocrinol. Metab., 1999, 13(4), 567-581.
31. Elenkov, I.J.; Chrousos, G.P. Stress Hormones, Th1/Th2 patterns, Pro/Anti-inflammatory Cytokines and Susceptibility to Disease. Trends Endocrinol. Metab., 1999, 10(9), 359-368.
32. Kubera, M.; Maes, M.; Kenis, G.; Kim, Y.K.; Lason, W. Effects of serotonin and serotonergic agonists and antagonists on the production of tumor necrosis factor alpha and interleukin-6. Psychiatry Res., 2005, 134(3), 251-258.
33. Muller, T.; Durk, T.; Blumenthal, B.; Grimm, M.; Cicko, S.; Panther, E.; Sorichter, S.; Herouy, Y.; Di Virgilio, F.; Ferrari, D.; Norgauer, J.; Idzko, M. 5-hydroxytryptamine modulates migration, cytokine and chemokine release and T-cell priming capacity of dendritic cells in vitro and in vivo. PLoS One, 2009, 4(7), e6453.
34. Jahnova, E. [The role of serotonin in the regulation of the immune response]. Bratisl Lek Listy, 1994, 95(4), 181-184.
35. Szabo, S.T.; de Montigny, C.; Blier, P. Progressive attenuation of the firing activity of locus coeruleus noradrenergic neurons by sustained administration of selective serotonin reuptake inhibitors. Int. J. Neuropsychopharmacol., 2000, 3(1), 1-11.
36. Di Giovanni, G.; Esposito, E.; Di Matteo, V. Role of serotonin in central dopamine dysfunction. CNS Neurosci. Ther., 2010, 16(3), 179-194.
37. Aosaki, T.; Miura, M.; Suzuki, T.; Nishimura, K.; Masuda, M. Acetylcholine-dopamine balance hypothesis in the striatum: an update. Geriatr. Gerontol. Int., 2010, 10 Suppl 1, S148-157.
38. Hoebel, B.G.; Avena, N.M.; Rada, P. Accumbens dopamineacetylcholine balance in approach and avoidance. Curr. Opin. Pharmacol., 2007, 7(6), 617-627.
39. Nakano, K.; Higashi, T.; Takagi, R.; Hashimoto, K.; Tanaka, Y.; Matsushita, S. Dopamine released by dendritic cells polarizes Th2 differentiation. Int. Immunol., 2009, 21(6), 645-654.
40. Ilani, T.; Strous, R.D.; Fuchs, S. Dopaminergic regulation of immune cells via D3 dopamine receptor: a pathway mediated by activated T cells. FASEB J., 2004, 18(13), 1600-1602.
41. Ghosh, M.C.; Mondal, A.C.; Basu, S.; Banerjee, S.; Majumder, J.; Bhattacharya, D.; Dasgupta, P.S. Dopamine inhibits cytokine release and expression of tyrosine kinases, Lck and Fyn in activated T cells. Int. Immunopharmacol., 2003, 3(7), 1019-1026.
42. Kikuchi, H.; Itoh, J.; Fukuda, S. Chronic nicotine stimulation modulates the immune response of mucosal T cells to Th1-dominant pattern via nAChR by upregulation of Th1-specific transcriptional factor. Neurosci. Lett., 2008, 432(3), 217-221.
43. Kuhlwein, E.; Irwin, M. Melatonin modulation of lymphocyte proliferation and Th1/Th2 cytokine expression. J. Neuroimmunol., 2001, 117(1-2), 51-57.
44. Garcia-Maurino, S.; Gonzalez-Haba, M.G.; Calvo, J.R.; Rafii-El-Idrissi, M.; Sanchez-Margalet, V.; Goberna, R.; Guerrero, J.M. Melatonin enhances IL-2, IL-6, and IFN-gamma production by human circulating CD4+ cells: a possible nuclear receptormediated mechanism involving T helper type 1 lymphocytes and monocytes. J. Immunol., 1997, 159(2), 574-581.
45. Levite, M. Neurotransmitters activate T-cells and elicit crucial functions via neurotransmitter receptors. Curr. Opin. Pharmacol., 2008, 8(4), 460-471.
46. Elenkov, I.J.; Chrousos, G.P. Stress system--organization, physiology and immunoregulation. Neuroimmunomodulation, 2006, 13(5-6), 257-267.
47. Lanfumey, L.; Mongeau, R.; Cohen-Salmon, C.; Hamon, M. Corticosteroid-serotonin interactions in the neurobiological mechanisms of stress-related disorders. Neurosci. Biobehav. Rev., 2008, 32(6), 1174-1184.
48. Wosiski-Kuhn, M.; Stranahan, A.M. Opposing effects of positive and negative stress on hippocampal plasticity over the lifespan. Ageing Res. Rev., 2011. [Epub ahea of print].
49. Branchi, I.; Francia, N.; Alleva, E. Epigenetic control of neurobehavioural plasticity: the role of neurotrophins. Behav. Pharmacol., 2004, 15(5-6), 353-362.
50. Kasakura, S. A role for T-helper type 1 and type 2 cytokines in the pathogenesis of various human diseases. Rinsho Byori, 1998, 46(9), 915-921.
51. Segal, B.M.; Dwyer, B.K.; Shevach, E.M. An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. J. Exp. Med., 1998, 187(4), 537-546.
52. Humbert, M.; Menz, G.; Ying, S.; Corrigan, C.J.; Robinson, D.S.; Durham, S.R.; Kay, A.B. The immunopathology of extrinsic (atopic) and intrinsic (non-atopic) asthma: more similarities than differences. Immunol. Today, 1999, 20(11), 528-533.
53. Wills-Karp, M. IL-12/IL-13 axis in allergic asthma. J. Allergy Clin. Immunol., 2001, 107(1), 9-18.
54. Link, H. The cytokine storm in multiple sclerosis. Mult. Scler., 1998, 4(1), 12-15.
55. Kato, H.; Suzumura, A. Cytokines in MS lesion. Nippon Rinsho, 2003, 61(8), 1428-1434.
56. Kang, B.Y.; Kim, T.S. Targeting cytokines of the interleukin-12 family in autoimmunity. Curr. Med. Chem., 2006, 13(10), 1149-1156.
57. Bennett, J.L.; Stuve, O. Update on inflammation, neurodegeneration, and immunoregulation in multiple sclerosis: therapeutic implications. Clin. Neuropharmacol., 2009, 32(3), 121-132.
58. Schmitz, T.; Chew, L.J. Cytokines and myelination in the central nervous system. Sci. World J., 2008, 8, 1119-1147.
59. Welsh, C.J.; Steelman, A.J.; Mi, W.; Young, C.R.; Dean, D.D.; Storts, R.; Welsh, T.H., Jr.; Meagher, M.W. Effects of stress on the immune response to Theiler's virus--implications for virus-induced autoimmunity. Neuroimmunomodulation, 2010, 17(3), 169-172.
60. Minagar, A.; Carpenter, A.; Alexander, J.S. The destructive alliance: interactions of leukocytes, cerebral endothelial cells, and the immune cascade in pathogenesis of multiple sclerosis. Int. Rev. Neurobiol., 2007, 79, 1-11.
61. Sospedra, M.; Martin, R. Immunology of multiple sclerosis. Annu. Rev. Immunol., 2005, 23, 683-747.
62. Vervoordeldonk, M.J.; Tak, P.P. Cytokines in rheumatoid arthritis. Curr. Rheumatol. Rep., 2002, 4(3), 208-217.
63. Miossec, P. Cytokines in rheumatoid arthritis: is it all TNF-alpha? Cell Mol Biol (Noisy-le-grand), 2001, 47(4), 675-678.
64. Umehara, H.; Tanaka, M.; Mimori, T. [Interferon-gamma in pathogenesis of rheumatoid arthritis]. Nippon Rinsho, 2005, 63 Suppl 1, 181-184.
65. Cornelissen, F.; van Hamburg, J.P.; Lubberts, E. The IL-12/IL-23 axis and its role in Th17 cell development, pathology and plasticity in arthritis. Curr. Opin. Investig. Drugs, 2009, 10(5), 452-462.
66. Malemud, C.J.; Miller, A.H. Pro-inflammatory cytokine-induced SAPK/MAPK and JAK/STAT in rheumatoid arthritis and the new anti-depression drugs. Expert Opin. Ther. Targets, 2008, 12(2), 171-183.
67. Knedla, A.; Neumann, E.; Muller-Ladner, U. Developments in the synovial biology field 2006. Arthritis Res. Ther., 2007, 9(2), 209.
68. Firestein, G.S. Immunologic mechanisms in the pathogenesis of rheumatoid arthritis. J. Clin. Rheumatol., 2005, 11(3 Suppl), S39-44.
69. Raza, K.; Falciani, F.; Curnow, S.J.; Ross, E.J.; Lee, C.Y.; Akbar, A.N.; Lord, J.M.; Gordon, C.; Buckley, C.D.; Salmon, M. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res. Ther., 2005, 7(4), R784-795.
70. Rabinovitch, A. An update on cytokines in the pathogenesis of insulin-dependent diabetes mellitus. Diabetes Metab. Rev., 1998, 14(2), 129-151.
71. Costa, V.S.; Mattana, T.C.; da Silva, M.E. Unregulated IL-23/IL-17 immune response in autoimmune diseases. Diabetes Res. Clin. Pract., 2010, 88(3), 222-226.
72. Bonifacio, E.; Scirpoli, M.; Kredel, K.; Fuchtenbusch, M.; Ziegler, A.G. Early autoantibody responses in prediabetes are IgG1 dominated and suggest antigen-specific regulation. J. Immunol., 1999, 163(1), 525-532.
73. Phenekos, C.; Vryonidou, A.; Gritzapis, A.D.; Baxevanis, C.N.; Goula, M.; Papamichail, M. Th1 and Th2 serum cytokine profiles characterize patients with Hashimoto's thyroiditis (Th1) and Graves' disease (Th2). Neuroimmunomodulation, 2004, 11(4), 209-213.
74. Lichiardopol, C.; Mota, M. The thyroid and autoimmunity. Rom. J. Intern. Med., 2009, 47(3), 207-215.
75. Ajjan, R.A.; Watson, P.F.; McIntosh, R.S.; Weetman, A.P. Intrathyroidal cytokine gene expression in Hashimoto's thyroiditis. Clin. Exp. Immunol., 1996, 105(3), 523-528.
76. Guo, J.; Rapoport, B.; McLachlan, S.M. Balance of Th1/Th2 cytokines in thyroid autoantibody synthesis in vitro. Autoimmunity, 1999, 30(1), 1-9.
77. de la Vega, J.R.; Vilaplana, J.C.; Biro, A.; Hammond, L.; Bottazzo, G.F.; Mirakian, R. IL-10 expression in thyroid glands: protective or harmful role against thyroid autoimmunity? Clin. Exp. Immunol., 1998, 113(1), 126-135.
78. Yamaguchi, Y.; Takahashi, H.; Satoh, T.; Okazaki, Y.; Mizuki, N.; Takahashi, K.; Ikezawa, Z.; Kuwana, M. Natural killer cells control a T-helper 1 response in patients with Behcet's disease. Arthritis Res. Ther., 2010, 12(3), R80.
79. Hamzaoui, K.; Ben Dhifallah, I.; Karray, E.; Sassi, F.H.; Hamzaoui, A. Vitamin D modulates peripheral immunity in patients with Behcet's disease. Clin. Exp. Rheumatol., 2010, 28(4 Suppl 60), S50-57.
80. Suzuki, H.; Suzuki, Y.; Aizawa, M.; Yamanaka, T.; Kihara, M.; Pang, H.; Horikoshi, S.; Tomino, Y. Th1 polarization in murine IgA nephropathy directed by bone marrow-derived cells. Kidney Int., 2007, 72(3), 319-327.
81. Lim, C.S.; Yoon, H.J.; Kim, Y.S.; Ahn, C.; Han, J.S.; Kim, S.; Lee, J.S.; Lee, H.S.; Chae, D.W. Clinicopathological correlation of intrarenal cytokines and chemokines in IgA nephropathy. Nephrology (Carlton), 2003, 8(1), 21-27.
82. Cutolo, M.; Foppiani, L.; Prete, C.; Ballarino, P.; Sulli, A.; Villaggio, B.; Seriolo, B.; Giusti, M.; Accardo, S. Hypothalamicpituitary-adrenocortical axis function in premenopausal women with rheumatoid arthritis not treated with glucocorticoids. J. Rheumatol., 1999, 26(2), 282-288.
83. Gudbjornsson, B.; Skogseid, B.; Oberg, K.; Wide, L.; Hallgren, R. Intact adrenocorticotropic hormone secretion but impaired cortisol response in patients with active rheumatoid arthritis. Effect of glucocorticoids. J. Rheumatol., 1996, 23(4), 596-602.
84. Neeck, G.; Federlin, K.; Graef, V.; Rusch, D.; Schmidt, K.L. Adrenal secretion of cortisol in patients with rheumatoid arthritis. J. Rheumatol., 1990, 17(1), 24-29.
85. Chikanza, I.C.; Petrou, P.; Kingsley, G.; Chrousos, G.; Panayi, G.S. Defective hypothalamic response to immune and inflammatory stimuli in patients with rheumatoid arthritis. Arthritis Rheum., 1992, 35(11), 1281-1288.
86. Mok, C.C.; Lau, C.S. Pathogenesis of systemic lupus erythematosus. J. Clin. Pathol., 2003, 56(7), 481-490.
87. Salem, M.L. Estrogen, a double-edged sword: modulation of TH1-and TH2-mediated inflammations by differential regulation of TH1/TH2 cytokine production. Curr. Drug Targets Inflamm. Allergy, 2004, 3(1), 97-104.
88. Mangini, A.J.; Lafyatis, R.; Van Seventer, J.M. Type I interferons inhibition of inflammatory T helper cell responses in systemic lupus erythematosus. Ann. N. Y. Acad. Sci., 2007, 1108, 11-23.
89. Gomez, D.; Correa, P.A.; Gomez, L.M.; Cadena, J.; Molina, J.F.; Anaya, J.M. Th1/Th2 cytokines in patients with systemic lupus erythematosus: is tumor necrosis factor alpha protective? Semin. Arthritis Rheum., 2004, 33(6), 404-413.
90. Mok, M.Y.; Wu, H.J.; Lo, Y.; Lau, C.S. The relation of interleukin 17 (IL-17) and IL-23 to Th1/Th2 cytokines and disease activity in systemic lupus erythematosus. J. Rheumatol., 2010, 37(10), 2046-2052.
91. Hayashi, T. Therapeutic strategies for SLE involving cytokines: mechanism-oriented therapies especially IFN-gamma targeting gene therapy. J. Biomed. Biotechnol., 2010, 2010, pii. 461641.
92. Calvani, N.; Tucci, M.; Richards, H.B.; Tartaglia, P.; Silvestris, F. Th1 cytokines in the pathogenesis of lupus nephritis: the role of IL-18. Autoimmun. Rev., 2005, 4(8), 542-548.
93. Nakashima, H.; Akahoshi, M.; Masutani, K. Th1/Th2 balance of SLE patients with lupus nephritis. Rinsho Byori, 2006, 54(7), 706-713.
94. Werfel, T. The role of leukocytes, keratinocytes, and allergenspecific IgE in the development of atopic dermatitis. J. Invest. Dermatol., 2009, 129(8), 1878-1891.
95. Levine, S.J.; Wenzel, S.E. Narrative review: the role of Th2 immune pathway modulation in the treatment of severe asthma and its phenotypes. Ann. Intern. Med., 2010, 152(4), 232-237.
96. Renauld, J.C. New insights into the role of cytokines in asthma. J. Clin. Pathol., 2001, 54(8), 577-589.
97. de Blic, J.; Tillie-Leblond, I.; Tonnel, A.B.; Jaubert, F.; Scheinmann, P.; Gosset, P. Difficult asthma in children: an analysis of airway inflammation. J. Allergy Clin. Immunol., 2004, 113(1), 94-100.
98. Pene, J.; Chevalier, S.; Preisser, L.; Venereau, E.; Guilleux, M.H.; Ghannam, S.; Moles, J.P.; Danger, Y.; Ravon, E.; Lesaux, S.; Yssel, H.; Gascan, H. Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. J. Immunol., 2008, 180(11), 7423-7430.
99. Meiler, F.; Zimmermann, M.; Blaser, K.; Akdis, C.A.; Akdis, M. T-cell subsets in the pathogenesis of human asthma. Curr. Allergy Asthma Rep., 2006, 6(2), 91-96.
100. Chaplin, D.D. Cell cooperation in development of eosinophilpredominant inflammation in airways. Immunol. Res., 2002, 26(1-3), 55-62.
101. Surendar, J.; Mohan, V.; Rao, M.M.; Babu, S.; Aravindhan, V. Increased Levels of Both Th1 and Th2 Cytokines in Subjects with Metabolic Syndrome (CURES-103). Diabetes Technol. Ther., 2011, 13(4), 477-482.
102. Elenkov, I.J.; Iezzoni, D.G.; Daly, A.; Harris, A.G.; Chrousos, G.P. Cytokine dysregulation, inflammation and well-being. Neuroimmunomodulation, 2005, 12(5), 255-269.
103. Stumpf, C.; Auer, C.; Yilmaz, A.; Lewczuk, P.; Klinghammer, L.; Schneider, M.; Daniel, W.G.; Schmieder, R.E.; Garlichs, C.D. Serum levels of the Th1 chemoattractant interferon-gammainducible protein (IP) 10 are elevated in patients with essential hypertension. Hypertens Res., 2011, 34(4), 484-488.
104. Chamontin, B. [The best of hypertension 2005]. Arch. Mal Coeur Vaiss, 2006, 99 Spec No 1(1), 35-41.
105. Lijnen, P.J.; Petrov, V.V.; Fagard, R.H. Association between transforming growth factor-beta and hypertension. Am. J. Hypertens, 2003, 16(7), 604-611.
106. Millis, R.M. Epigenetics and hypertension. Curr. Hypertens Rep., 2011, 13(1), 21-28.
107. Esler, M.; Eikelis, N.; Schlaich, M.; Lambert, G.; Alvarenga, M.; Kaye, D.; El-Osta, A.; Guo, L.; Barton, D.; Pier, C.; Brenchley, C.; Dawood, T.; Jennings, G.; Lambert, E. Human sympathetic nerve biology: parallel influences of stress and epigenetics in essential hypertension and panic disorder. Ann. N. Y. Acad. Sci., 2008, 1148, 338-348.
108. al'Absi, M.; Arnett, D.K. Adrenocortical responses to psychological stress and risk for hypertension. Biomed. Pharmacother., 2000, 54(5), 234-244.
109. Whitworth, J.A.; Brown, M.A.; Kelly, J.J.; Williamson, P.M. Mechanisms of cortisol-induced hypertension in humans. Steroids, 1995, 60(1), 76-80.
110. Shamshiev, A.T.; Ampenberger, F.; Ernst, B.; Rohrer, L.; Marsland, B.J.; Kopf, M. Dyslipidemia inhibits Toll-like receptorinduced activation of CD8alpha-negative dendritic cells and protective Th1 type immunity. J. Exp. Med., 2007, 204(2), 441-452.
111. Zhou, X.; Paulsson, G.; Stemme, S.; Hansson, G.K. Hypercholesterolemia is associated with a T helper (Th) 1/Th2 switch of the autoimmune response in atherosclerotic apo Eknockout mice. J. Clin. Invest., 1998, 101(8), 1717-1725.
112. Arner, P. Catecholamine-induced lipolysis in obesity. Int. J. Obes. Relat. Metab. Disord., 1999, 23 Suppl 1, 10-13.
113. Brillon, D.J.; Zheng, B.; Campbell, R.G.; Matthews, D.E. Effect of cortisol on energy expenditure and amino acid metabolism in humans. Am. J. Physiol., 1995, 268(3 Pt 1), E501-513.
114. Rocha, V.Z.; Folco, E.J.; Sukhova, G.; Shimizu, K.; Gotsman, I.; Vernon, A.H.; Libby, P. Interferon-gamma, a Th1 cytokine, regulates fat inflammation: a role for adaptive immunity in obesity. Circ. Res., 2008, 103(5), 467-476.
115. Bertola, A.; Bonnafous, S.; Anty, R.; Patouraux, S.; Saint-Paul, M.C.; Iannelli, A.; Gugenheim, J.; Barr, J.; Mato, J.M.; Le Marchand-Brustel, Y.; Tran, A.; Gual, P. Hepatic expression patterns of inflammatory and immune response genes associated with obesity and NASH in morbidly obese patients. PLoS One, 2010, 5(10), e13577.
116. Meshkani, R.; Adeli, K. Hepatic insulin resistance, metabolic syndrome and cardiovascular disease. Clin. Biochem., 2009, 42(13-14), 1331-1346.
117. Fain, J.N. Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. Vitam. Horm, 2006, 74, 443-477.
118. Pacifico, L.; Di Renzo, L.; Anania, C.; Osborn, J.F.; Ippoliti, F.; Schiavo, E.; Chiesa, C. Increased T-helper interferon-gammasecreting cells in obese children. Eur. J. Endocrinol., 2006, 154(5), 691-697.
119. Schmidt, M.V.; Czisch, M.; Sterlemann, V.; Reinel, C.; Samann, P.; Muller, M.B. Chronic social stress during adolescence in mice alters fat distribution in late life: prevention by antidepressant treatment. Stress, 2009, 12(1), 89-94.
120. Drapeau, V.; Therrien, F.; Richard, D.; Tremblay, A. Is visceral obesity a physiological adaptation to stress? Panminerva Med., 2003, 45(3), 189-195.
121. Kyrou, I.; Chrousos, G.P.; Tsigos, C. Stress, visceral obesity, and metabolic complications. Ann. N. Y. Acad. Sci., 2006, 1083, 77-110.
122. Hamdy, O.; Porramatikul, S.; Al-Ozairi, E. Metabolic obesity: the paradox between visceral and subcutaneous fat. Curr. Diabetes Rev., 2006, 2(4), 367-373.
123. Yudkin, J.S. Inflammation, obesity, and the metabolic syndrome. Horm. Metab. Res., 2007, 39(10), 707-709.
124. Borst, S.E. The role of TNF-alpha in insulin resistance. Endocrine, 2004, 23(2-3), 177-182.
125. Jagannathan-Bogdan, M.; McDonnell, M.E.; Shin, H.; Rehman, Q.; Hasturk, H.; Apovian, C.M.; Nikolajczyk, B.S. Elevated proinflammatory cytokine production by a skewed T cell compartment requires monocytes and promotes inflammation in type 2 diabetes. J. Immunol., 2011, 186(2), 1162-1172.
126. Viardot, A.; Grey, S.T.; Mackay, F.; Chisholm, D. Potential antiinflammatory role of insulin via the preferential polarization of effector T cells toward a T helper 2 phenotype. Endocrinology, 2007, 148(1), 346-353.
127. Jawien, J. New insights into immunological aspects of atherosclerosis. Pol. Arch. Med. Wewn, 2008, 118(3), 127-131.
128. Rodriguez, G.; Mago, N.; Rosa, F. [Role of inflammation in atherogenesis]. Invest. Clin., 2009, 50(1), 109-129.
129. Hansson, G.K. Inflammatory mechanisms in atherosclerosis. J. Thromb. Haemost., 2009, 7 Suppl 1, 328-331.
130. Huber, S.A.; Sakkinen, P.; David, C.; Newell, M.K.; Tracy, R.P. T helper-cell phenotype regulates atherosclerosis in mice under conditions of mild hypercholesterolemia. Circulation, 2001, 103(21), 2610-2616.
131. Greaves, D.R.; Channon, K.M. Inflammation and immune responses in atherosclerosis. Trends Immunol., 2002, 23(11), 535-541.
132. Shinozawa, Y.; Xie, X.Q.; Endo, T.; Takuma, K.; Koike, K. [Correlation between intravascular coagulation/fibrinolysis system and cytokines]. Nippon Rinsho, 2004, 62(12), 2253-2261.
133. Chu, A.J. Blood coagulation as an intrinsic pathway for proinflammation: a mini review. Inflamm. Allergy Drug Targets, 2010, 9(1), 32-44.
134. Devaraj, S.; Rosenson, R.S.; Jialal, I. Metabolic syndrome: an appraisal of the pro-inflammatory and procoagulant status. Endocrinol. Metab. Clin. North Am., 2004, 33(2), 431-453, table of contents.
135. Gando, S. Microvascular thrombosis and multiple organ dysfunction syndrome. Crit. Care Med., 2010, 38(2 Suppl), S35-42.
136. De Cicco, M. The prothrombotic state in cancer: pathogenic mechanisms. Crit. Rev. Oncol. Hematol., 2004, 50(3), 187-196.
137. Cheng, X.; Liao, Y.H.; Li, B.; Zhang, J.Y.; Ge, H.X.; Yuan, J.; Wang, M.; Liu, Y.; Guo, Z.Q.; Chen, J.; Zhang, J.; Chen, P. [The significance of Th1/Th2 function imbalance in patients with postinfarction cardiac insufficiency]. Zhonghua Xin Xue Guan Bing Za Zhi, 2005, 33(6), 526-528.
138. Cheng, X.; Ding, Y.; Xia, C.; Tang, T.; Yu, X.; Xie, J.; Liao, M.; Yao, R.; Chen, Y.; Wang, M.; Liao, Y.H. Atorvastatin modulates Th1/Th2 response in patients with chronic heart failure. J. Card. Fail., 2009, 15(2), 158-162.
139. Cheng, X.; Liao, Y.H.; Zhang, J.; Li, B.; Ge, H.; Yuan, J.; Wang, M.; Lu, B.; Liu, Y.; Cheng, Y. Effects of Atorvastatin on Th polarization in patients with acute myocardial infarction. Eur. J. Heart Fail., 2005, 7(7), 1099-1104.
140. Vlastelica, M. Emotional stress as a trigger in sudden cardiac death. Psychiatr. Danub, 2008, 20(3), 411-414.
141. Zupancic, M.L. Acute psychological stress as a precipitant of acute coronary syndromes in patients with undiagnosed ischemic heart disease: a case report and literature review. Prim. Care Companion J. Clin. Psychiatry, 2009, 11(1), 21-24.
142. Bossowska, A.; Kiersnowska-Rogowska, B.; Bossowski, A.; Galar, B.; Sowinski, P. Cytokines in patients with ischaemic heart disease or myocardial infarction. Kardiol. Pol., 2003, 59(8), 105-114.
143. Hartford, M.; Wiklund, O.; Mattsson Hulten, L.; Perers, E.; Person, A.; Herlitz, J.; Hurt-Camejo, E.; Karlsson, T.; Caidahl, K. CRP, interleukin-6, secretory phospholipase A2 group IIA, and intercellular adhesion molecule-1 during the early phase of acute coronary syndromes and long-term follow-up. Int. J. Cardiol., 2006, 108(1), 55-62.
144. Riese, U.; Brenner, S.; Docke, W.D.; Prosch, S.; Reinke, P.; Oppert, M.; Volk, H.D.; Platzer, C. Catecholamines induce IL-10 release in patients suffering from acute myocardial infarction by transactivating its promoter in monocytic but not in T-cells. Mol. Cell Biochem., 2000, 212(1-2), 45-50.
145. Platzer, C.; Docke, W.; Volk, H.; Prosch, S. Catecholamines trigger IL-10 release in acute systemic stress reaction by direct stimulation of its promoter/enhancer activity in monocytic cells. J. Neuroimmunol., 2000, 105(1), 31-38.
146. Wei, L. Immunological aspect of cardiac remodeling: T lymphocyte subsets in inflammation-mediated cardiac fibrosis. Exp. Mol. Pathol., 2011, 90(1), 74-78.
147. Gage, J.R.; Fonarow, G.; Hamilton, M.; Widawski, M.; Martinez-Maza, O.; Vredevoe, D.L. Beta blocker and angiotensin-converting enzyme inhibitor therapy is associated with decreased Th1/Th2 cytokine ratios and inflammatory cytokine production in patients with chronic heart failure. Neuroimmunomodulation, 2004, 11(3), 173-180.
148. Shenhar-Tsarfaty, S.; Assayag, E.B.; Bova, I.; Shopin, L.; Berliner, S.; Shapira, I.; Bornstein, N.M. Early signaling of inflammation in acute ischemic stroke: clinical and rheological implications. Thromb. Res., 2008, 122(2), 167-173.
149. Vila, N.; Castillo, J.; Davalos, A.; Chamorro, A. Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke, 2000, 31(10), 2325-2329.
150. Okazaki, K.; Nishida, A.; Kato, M.; Kozawa, K.; Uga, N.; Kimura, H. Elevation of cytokine concentrations in asphyxiated neonates. Biol. Neonate, 2006, 89(3), 183-189.
151. Santos, M.; Kovari, E.; Gold, G.; Bozikas, V.P.; Hof, P.R.; Bouras, C.; Giannakopoulos, P. The neuroanatomical model of post-stroke depression: towards a change of focus? J. Neurol. Sci., 2009, 283(1-2), 158-162.
152. Nestle, F.O.; Turka, L.A.; Nickoloff, B.J. Characterization of dermal dendritic cells in psoriasis. Autostimulation of T lymphocytes and induction of Th1 type cytokines. J. Clin. Invest., 1994, 94(1), 202-209.
153. Vena, G.A.; Vestita, M.; Cassano, N. Psoriasis and cardiovascular disease. Dermatol. Ther., 2010, 23(2), 144-151.
154. Hodge, G.; Nairn, J.; Holmes, M.; Reynolds, P.N.; Hodge, S. Increased intracellular T helper 1 proinflammatory cytokine production in peripheral blood, bronchoalveolar lavage and intraepithelial T cells of COPD subjects. Clin. Exp. Immunol., 2007, 150(1), 22-29.
155. Macario, C.C.; Torres Tajes, J.P.; Cordoba Lanus, E. [COPD: bronchial and systemic inflammation]. Arch. Bronconeumol., 2010, 46 Suppl 4, 9-15.
156. Bouma, G.; Strober, W. The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol., 2003, 3(7), 521-533.
157. De Martinis, M.; Di Benedetto, M.C.; Mengoli, L.P.; Ginaldi, L. Senile osteoporosis: is it an immune-mediated disease? Inflamm. Res., 2006, 55(10), 399-404.
158. Sandmand, M.; Bruunsgaard, H.; Kemp, K.; Andersen-Ranberg, K.; Pedersen, A.N.; Skinhoj, P.; Pedersen, B.K. Is ageing associated with a shift in the balance between Type 1 and Type 2 cytokines in humans? Clin. Exp. Immunol., 2002, 127(1), 107-114.
159. Ginaldi, L.; De Martinis, M.; D'Ostilio, A.; Marini, L.; Loreto, M.F.; Quaglino, D. The immune system in the elderly: III. Innate immunity. Immunol. Res., 1999, 20(2), 117-126.
160. Chan, E.C.; Smith, R.; Lewin, T.; Brinsmead, M.W.; Zhang, H.P.; Cubis, J.; Thornton, K.; Hurt, D. Plasma corticotropin-releasing hormone, beta-endorphin and cortisol inter-relationships during human pregnancy. Acta Endocrinol. (Copenh), 1993, 128(4), 339-344.
161. Dantzer, R.; Wollman, E.; Vitkovic, L.; Yirmiya, R. Cytokines and depression: fortuitous or causative association? Mol. Psychiatry, 1999, 4(4), 328-332.
162. Hashioka, S.; McGeer, P.L.; Monji, A.; Kanba, S. Antiinflammatory effects of antidepressants: possibilities for preventives against Alzheimer's disease. Cent. Nerv. Syst. Agents Med. Chem., 2009, 9(1), 12-19.
163. Nagatsu, T.; Sawada, M. Inflammatory process in Parkinson's disease: role for cytokines. Curr. Pharm. Des., 2005, 11(8), 999-1016.
164. Sawada, M.; Imamura, K.; Nagatsu, T. Role of cytokines in inflammatory process in Parkinson's disease. J. Neural. Transm. Suppl., 2006, (70), 373-381.
165. Brodacki, B.; Staszewski, J.; Toczylowska, B.; Kozlowska, E.; Drela, N.; Chalimoniuk, M.; Stepien, A. Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFalpha, and INFgamma concentrations are elevated in patients with atypical and idiopathic parkinsonism. Neurosci. Lett., 2008, 441(2), 158-162.
166. Nagatsu, T.; Mogi, M.; Ichinose, H.; Togari, A. Changes in cytokines and neurotrophins in Parkinson's disease. J. Neural. Transm. Suppl., 2000, vol. (60), 277-290.
167. Nagatsu, T.; Mogi, M.; Ichinose, H.; Togari, A. Cytokines in Parkinson's disease. J. Neural. Transm. Suppl, 2000, vol. (58), 143-151.
168. Mount, M.P.; Lira, A.; Grimes, D.; Smith, P.D.; Faucher, S.; Slack, R.; Anisman, H.; Hayley, S.; Park, D.S. Involvement of interferongamma in microglial-mediated loss of dopaminergic neurons. J. Neurosci., 2007, 27(12), 3328-3337.
169. Mihara, T.; Nakashima, M.; Kuroiwa, A.; Akitake, Y.; Ono, K.; Hosokawa, M.; Yamada, T.; Takahashi, M. Natural killer cells of Parkinson's disease patients are set up for activation: a possible role for innate immunity in the pathogenesis of this disease. Parkinsonism Relat. Disord., 2008, 14(1), 46-51.
170. Baba, Y.; Kuroiwa, A.; Uitti, R.J.; Wszolek, Z.K.; Yamada, T. Alterations of T-lymphocyte populations in Parkinson disease. Parkinsonism Relat. Disord., 2005, 11(8), 493-498.
171. Arimoto, T.; Choi, D.Y.; Lu, X.; Liu, M.; Nguyen, X.V.; Zheng, N.; Stewart, C.A.; Kim, H.C.; Bing, G. Interleukin-10 protects against inflammation-mediated degeneration of dopaminergic neurons in substantia nigra. Neurobiol. Aging, 2006, 28(6), 894-906.
172. Johnston, L.C.; Su, X.; Maguire-Zeiss, K.; Horovitz, K.; Ankoudinova, I.; Guschin, D.; Hadaczek, P.; Federoff, H.J.; Bankiewicz, K.; Forsayeth, J. Human interleukin-10 gene transfer is protective in a rat model of Parkinson's disease. Mol. Ther., 2008, 16(8), 1392-1399.
173. Engler, H.; Doenlen, R.; Riether, C.; Engler, A.; Niemi, M.B.; Besedovsky, H.O.; del Rey, A.; Pacheco-Lopez, G.; Feldon, J.; Schedlowski, M. Time-dependent alterations of peripheral immune parameters after nigrostriatal dopamine depletion in a rat model of Parkinson's disease. Brain Behav. Immun., 2009, 23(4), 518-526.
174. Kluter, H.; Vieregge, P.; Stolze, H.; Kirchner, H. Defective production of interleukin-2 in patients with idiopathic Parkinson's disease. J. Neurol. Sci., 1995, 133(1-2), 134-139.
175. Reale, M.; Iarlori, C.; Feliciani, C.; Gambi, D. Peripheral chemokine receptors, their ligands, cytokines and Alzheimer's disease. J. Alzheimers Dis., 2008, 14(2), 147-159.
176. Cao, C.; Arendash, G.W.; Dickson, A.; Mamcarz, M.B.; Lin, X.; Ethell, D.W. Abeta-specific Th2 cells provide cognitive and pathological benefits to Alzheimer's mice without infiltrating the CNS. Neurobiol. Dis., 2009, 34(1), 63-70.
177. Kim, H.D.; Tahara, K.; Maxwell, J.A.; Lalonde, R.; Fukuiwa, T.; Fujihashi, K.; Van Kampen, K.R.; Kong, F.K.; Tang, D.C.; Fukuchi, K. Nasal inoculation of an adenovirus vector encoding 11 tandem repeats of Abeta1-6 upregulates IL-10 expression and reduces amyloid load in a Mo/Hu APPswe PS1dE9 mouse model of Alzheimer's disease. J. Gene Med., 2007, 9(2), 88-98.
178. Gadient, R.A.; Otten, U.H. Interleukin-6 (IL-6)--a molecule with both beneficial and destructive potentials. Prog. Neurobiol., 1997, 52(5), 379-390.
179. Fitzgerald, P.J. Is elevated norepinephrine an etiological factor in some cases of Alzheimer's disease? Curr. Alzheimer Res., 2010, 7(6), 506-516.
180. Clerici, M.; Shearer, G.M. A TH1-->TH2 switch is a critical step in the etiology of HIV infection. Immunol. Today, 1993, 14(3), 107-111.
181. Capitanio, J.P.; Abel, K.; Mendoza, S.P.; Blozis, S.A.; McChesney, M.B.; Cole, S.W.; Mason, W.A. Personality and serotonin transporter genotype interact with social context to affect immunity and viral set-point in simian immunodeficiency virus disease. Brain Behav. Immun., 2008, 22(5), 676-689.
182. Capitanio, J.P.; Lerche, N.W. Psychosocial factors and disease progression in simian AIDS: a preliminary report. AIDS, 1991, 5(9), 1103-1106.
183. Reilly, K.H.; Clark, R.A.; Schmidt, N.; Benight, C.C.; Kissinger, P. The effect of post-traumatic stress disorder on HIV disease progression following hurricane Katrina. AIDS Care, 2009, 21(10), 1298-1305.
184. Gore-Felton, C.; Koopman, C. Behavioral mediation of the relationship between psychosocial factors and HIV disease progression. Psychosom. Med., 2008, 70(5), 569-574.
185. Fleshner, M.; Brennan, F.X.; Nguyen, K.; Watkins, L.R.; Maier, S.F. RU-486 blocks differentially suppressive effect of stress on in vivo anti-KLH immunoglobulin response. Am. J. Physiol., 1996, 271(5 Pt 2), R1344-1352.
186. Pacifici, R.; Zuccaro, P.; Hernandez Lopez, C.; Pichini, S.; Di Carlo, S.; Farre, M.; Roset, P.N.; Ortuno, J.; Segura, J.; Torre, R.L. Acute effects of 3,4-methylenedioxymethamphetamine alone and in combination with ethanol on the immune system in humans. J. Pharmacol. Exp. Ther., 2001, 296(1), 207-215.
187. Miller, G.; Chen, E.; Cole, S.W. Health psychology: developing biologically plausible models linking the social world and physical health. Annu. Rev. Psychol., 2009, 60, 501-524.
188. Becker, Y. The changes in the T helper 1 (Th1) and T helper 2 (Th2) cytokine balance during HIV-1 infection are indicative of an allergic response to viral proteins that may be reversed by Th2 cytokine inhibitors and immune response modifiers--a review and hypothesis. Virus Genes, 2004, 28(1), 5-18.
189. Rook, G.A.; Onyebujoh, P.; Stanford, J.L. TH1/TH2 switching and loss of CD4+ T cells in chronic infections: an immunoendocrinological hypothesis not exclusive to HIV. Immunol. Today, 1993, 14(11), 568-569.
190. Pawlowska, M. [HCV: immune response and its modifiers in clinical development]. Przegl. Epidemiol., 2005, 59(2), 519-523.
191. Par, G.; Berki, T.; Palinkas, L.; Balogh, P.; Szereday, L.; Halasz, M.; Szekeres-Bartho, J.; Miseta, A.; Hegedus, G.; Mozsik, G.; Hunyady, B.; Par, A. [Immunology of HCV infection: the causes of impaired cellular immune response and the effect of antiviral treatment]. Orv. Hetil., 2006, 147(13), 591-600.
192. Trapero, M.; Garcia-Buey, L.; Munoz, C.; Viton, M.; Moreno-Monteagudo, J.A.; Borque, M.J.; Quintana, N.E.; Moreno-Otero, R. Maintenance of T1 response as induced during PEG-IFNalpha plus ribavirin therapy controls viral replication in genotype-1 patients with chronic hepatitis C. Rev. Esp. Enferm. Dig., 2005, 97(7), 481-490.
193. Hukkanen, V.; Broberg, E.; Salmi, A.; Eralinna, J.P. Cytokines in experimental herpes simplex virus infection. Int. Rev. Immunol., 2002, 21(4-5), 355-371.
194. Miller, R.L.; Tomai, M.A.; Harrison, C.J.; Bernstein, D.I. Immunomodulation as a treatment strategy for genital herpes: review of the evidence. Int. Immunopharmacol., 2002, 2(4), 443-451.
195. Hengge, U.R.; Benninghoff, B.; Ruzicka, T.; Goos, M. Topical immunomodulators--progress towards treating inflammation, infection, and cancer. Lancet Infect. Dis., 2001, 1(3), 189-198.
196. Reiner, S.L.; Locksley, R.M. Cytokines in the differentiation of Th1/Th2 CD4+ subsets in leishmaniasis. J. Cell Biochem., 1993, 53(4), 323-328.
197. Fitzgerald, T.J. The Th1/Th2-like switch in syphilitic infection: is it detrimental? Infect. Immun., 1992, 60(9), 3475-3479.
198. He, X.Y.; Xiao, L.; Chen, H.B.; Hao, J.; Li, J.; Wang, Y.J.; He, K.; Gao, Y.; Shi, B.Y. T regulatory cells and Th1/Th2 cytokines in peripheral blood from tuberculosis patients. Eur. J. Clin. Microbiol. Infect. Dis., 2010, 29(6), 643-650.
199. Lienhardt, C.; Azzurri, A.; Amedei, A.; Fielding, K.; Sillah, J.; Sow, O.Y.; Bah, B.; Benagiano, M.; Diallo, A.; Manetti, R.; Manneh, K.; Gustafson, P.; Bennett, S.; D'Elios, M.M.; McAdam, K.; Del Prete, G. Active tuberculosis in Africa is associated with reduced Th1 and increased Th2 activity in vivo. Eur. J. Immunol., 2002, 32(6), 1605-1613.
200. Garcia, M.; Vargas, J.A.; Castejon, R.; Navas, E.; Durantez, A. Flow-cytometric assessment of lymphocyte cytokine production in tuberculosis. Tuberculosis (Edinb), 2002, 82(1), 37-41.
201. Kelestimur, F. The endocrinology of adrenal tuberculosis: the effects of tuberculosis on the hypothalamo-pituitary-adrenal axis and adrenocortical function. J. Endocrinol. Invest., 2004, 27(4), 380-386.
202. Patel, S.A.; Ndabahaliye, A.; Lim, P.K.; Milton, R.; Rameshwar, P. Challenges in the development of future treatments for breast cancer stem cells. Breast Cancer (London), 2010, 2, 1-11.
203. Moeller, M.; Kershaw, M.H.; Cameron, R.; Westwood, J.A.; Trapani, J.A.; Smyth, M.J.; Darcy, P.K. Sustained antigenspecific antitumor recall response mediated by gene-modified CD4+ T helper-1 and CD8+ T cells. Cancer Res., 2007, 67(23), 11428-11437.
204. Scola, L.; Giacalone, A.; Marasa, L.; Mirabile, M.; Vaccarino, L.; Forte, G.I.; Giannitrapani, L.; Caruso, C.; Montalto, G.; Lio, D. Genetic determined downregulation of both type 1 and type 2 cytokine pathways might be protective against pancreatic cancer. Ann. N. Y. Acad. Sci., 2009, 1155, 284-288.
205. Lissoni, P.; Rovelli, F.; Tisi, E.; Brivio, F.; Ardizzoia, A.; Barni, S.; Tancini, G.; Saudelli, M.; Cesana, E.; Vigano, M.G. Relation between macrophage and T helper-2 lymphocyte functions in human neoplasms: neopterin, interleukin-10 and interleukin-6 blood levels in early or advanced solid tumors. J. Biol. Regul. Homeost. Agents, 1995, 9(4), 146-149.
206. Budhu, A.; Forgues, M.; Ye, Q.H.; Jia, H.L.; He, P.; Zanetti, K.A.; Kammula, U.S.; Chen, Y.; Qin, L.X.; Tang, Z.Y.; Wang, X.W. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell, 2006, 10(2), 99-111.
207. Budhu, A.; Wang, X.W. The role of cytokines in hepatocellular carcinoma. J. Leukoc. Biol., 2006, 80(6), 1197-1213.
208. Sparano, A.; Lathers, D.M.; Achille, N.; Petruzzelli, G.J.; Young, M.R. Modulation of Th1 and Th2 cytokine profiles and their association with advanced head and neck squamous cell carcinoma. Otolaryngol. Head Neck Surg., 2004, 131(5), 573-576.
209. Pries, R.; Wollenberg, B. Cytokines in head and neck cancer. Cytokine Growth Factor Rev., 2006, 17(3), 141-146.
210. Chen, X.; Xu, X.; Zhao, J.; Zhu, L.; Xue, A.; Zhang, D. [The gene expression of Th1/Th2 cytokines and its role in hypopharyngeal carcinoma]. Lin Chuang Er Bi Yan Hou Ke Za Zhi, 2004, 18(6), 327-328.
211. Wei, Y.C.; Hu, F.B.; Shen, Y.; Xu, L.H.; Lin, L.S. [Postoperative Th1 and Th2 type cytokine changes in patients with esophageal squamous cell carcinoma and their clinical significance]. Di Yi Jun Yi Da Xue Xue Bao, 2004, 24(11), 1271-1273.
212. Yamazaki, K.; Yano, T.; Kameyama, T.; Suemitsu, R.; Yoshino, I.; Sugio, K. Clinical significance of serum TH1/TH2 cytokines in patients with pulmonary adenocarcinoma. Surgery, 2002, 131(1 Suppl), S236-241.
213. Teschendorff, A.E.; Gomez, S.; Arenas, A.; El-Ashry, D.; Schmidt, M.; Gehrmann, M.; Caldas, C. Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules. BMC Cancer, 2010, 10, 604.
214. Kobayashi, M.; Kobayashi, H.; Pollard, R.B.; Suzuki, F. A pathogenic role of Th2 cells and their cytokine products on the pulmonary metastasis of murine B16 melanoma. J. Immunol., 1998, 160(12), 5869-5873.
215. Weng, A.P.; Shahsafaei, A.; Dorfman, D.M. CXCR4/CD184 immunoreactivity in T-cell non-Hodgkin lymphomas with an overall Th1-Th2+ immunophenotype. Am. J. Clin. Pathol., 2003, 119(3), 424-430.
216. Rico, M.J.; Matar, P.; Gervasoni, S.I.; Bonfil, R.D.; Calcaterra, N.; Scharovsky, O.G. The transition to the metastatic phenotype of rat lymphoma cells involves up-regulation of IL-10 receptor expression and IL-10 secretion. Clin. Exp. Metastasis, 2005, 22(2), 127-135.
217. Bellone, G.; Turletti, A.; Artusio, E.; Mareschi, K.; Carbone, A.; Tibaudi, D.; Robecchi, A.; Emanuelli, G.; Rodeck, U. Tumorassociated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am. J. Pathol., 1999, 155(2), 537-547.
218. Feurino, L.W.; Zhang, Y.; Bharadwaj, U.; Zhang, R.; Li, F.; Fisher, W.E.; Brunicardi, F.C.; Chen, C.; Yao, Q.; Min, L. IL-6 stimulates Th2 type cytokine secretion and upregulates VEGF and NRP-1 expression in pancreatic cancer cells. Cancer Biol. Ther., 2007, 6(7), 1096-1100.
219. Tassi, E.; Braga, M.; Longhi, R.; Gavazzi, F.; Parmiani, G.; Di Carlo, V.; Protti, M.P. Non-redundant role for IL-12 and IL-27 in modulating Th2 polarization of carcinoembryonic antigen specific CD4 T cells from pancreatic cancer patients. PLoS One, 2009, 4(10), e7234.
220. Reiche, E.M.; Morimoto, H.K.; Nunes, S.M. Stress and depressioninduced immune dysfunction: implications for the development and progression of cancer. Int. Rev. Psychiatry, 2005, 17(6), 515-527.
221. Yang, M.; Ma, C.; Liu, S.; Sun, J.; Shao, Q.; Gao, W.; Zhang, Y.; Li, Z.; Xie, Q.; Dong, Z.; Qu, X. Hypoxia skews dendritic cells to a T helper type 2-stimulating phenotype and promotes tumour cell migration by dendritic cell-derived osteopontin. Immunology, 2009, 128(1 Suppl), e237-249.
222. Basso, A.M.; Depiante-Depaoli, M.; Molina, V.A. Chronic variable stress facilitates tumoral growth: reversal by imipramine administration. Life Sci., 1992, 50(23), 1789-1796.
223. Palesh, O.; Butler, L.D.; Koopman, C.; Giese-Davis, J.; Carlson, R.; Spiegel, D. Stress history and breast cancer recurrence. J. Psychosom. Res., 2007, 63(3), 233-239.
224. Katz, J.B.; Muller, A.J.; Prendergast, G.C. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol. Rev., 2008, 222, 206-221.
225. Schrocksnadel, K.; Wirleitner, B.; Winkler, C.; Fuchs, D. Monitoring tryptophan metabolism in chronic immune activation. Clin. Chim. Acta, 2006, 364(1-2), 82-90.
226. Tanke, M.A.; Kema, I.P.; Dijck-Brouwer, J.; Doornbos, B.; De Vries, E.G.; Korf, J. Low plasma tryptophan in carcinoid patients is associated with increased urinary cortisol excretion. Psychoneuroendocrinology, 2008, 33(9), 1297-1301.
227. Brandacher, G.; Winkler, C.; Schroecksnadel, K.; Margreiter, R.; Fuchs, D. Antitumoral activity of interferon-gamma involved in impaired immune function in cancer patients. Curr. Drug Metab., 2006, 7(6), 599-612.
228. Zeng, J.; Cai, S.; Yi, Y.; He, Y.; Wang, Z.; Jiang, G.; Li, X.; Du, J. Prevention of spontaneous tumor development in a ret transgenic mouse model by ret peptide vaccination with indoleamine 2,3-dioxygenase inhibitor 1-methyl tryptophan. Cancer Res., 2009, 69(9), 3963-3970.
229. Boasso, A.; Shearer, G.M. How does indoleamine 2,3-dioxygenase contribute to HIV-mediated immune dysregulation. Curr. Drug Metab., 2007, 8(3), 217-223.
230. Opitz, C.A.; Wick, W.; Steinman, L.; Platten, M. Tryptophan degradation in autoimmune diseases. Cell Mol. Life Sci., 2007, 64(19-20), 2542-2563.
231. Criado, G.; Simelyte, E.; Inglis, J.J.; Essex, D.; Williams, R.O. Indoleamine 2,3 dioxygenase-mediated tryptophan catabolism regulates accumulation of Th1/Th17 cells in the joint in collageninduced arthritis. Arthritis Rheum., 2009, 60(5), 1342-1351.
232. Pertovaara, M.; Hasan, T.; Raitala, A.; Oja, S.S.; Yli-Kerttula, U.; Korpela, M.; Hurme, M. Indoleamine 2,3-dioxygenase activity is increased in patients with systemic lupus erythematosus and predicts disease activation in the sunny season. Clin. Exp. Immunol., 2007, 150(2), 274-278.
233. Harvie, M.N.; Campbell, I.T.; Howell, A.; Thatcher, N. Acceptability and tolerance of a low tyrosine and phenylalanine diet in patients with advanced cancer--a pilot study. J. Hum. Nutr. Diet., 2002, 15(3), 193-202.
234. Matar, P.; Rozados, V.R.; Gervasoni, S.I.; Scharovsky, G.O. Th2/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma model. Cancer Immunol. Immunother., 2002, 50(11), 588-596.
235. Fishman, M.A.; Perelson, A.S. Th1/Th2 cross regulation. J. Theor. Biol., 1994, 170(1), 25-56.
236. Ader, R., Felten, D.L., Cohen, N. Psychoneuroimmunology. Academic Press, San Diego California, USA. 2001.
237. Dowlati, Y.; Herrmann, N.; Swardfager, W.; Liu, H.; Sham, L.; Reim, E.K.; Lanctot, K.L. A meta-analysis of cytokines in major depression. Biol. Psychiatry, 2010, 67(5), 446-457.
238. Schlatter, J.; Ortuno, F.; Cervera-Enguix, S. Monocytic parameters in patients with dysthymia versus major depression. J. Affect. Disord., 2004, 78(3), 243-247.
239. Maes, M. Major depression and activation of the inflammatory response system. Adv. Exp. Med. Biol., 1999, 461, 25-46.
240. Lanquillon, S.; Krieg, J.C.; Bening-Abu-Shach, U.; Vedder, H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology, 2000, 22(4), 370-379.
241. Axelson, D.A.; Doraiswamy, P.M.; McDonald, W.M.; Boyko, O.B.; Tupler, L.A.; Patterson, L.J.; Nemeroff, C.B.; Ellinwood, E.H., Jr.; Krishnan, K.R. Hypercortisolemia and hippocampal changes in depression. Psychiatry Res., 1993, 47(2), 163-173.
242. Cleare, A.J. Reduced whole blood serotonin in major depression. Depress Anxiety, 1997, 5(2), 108-111.
243. Leonard, B.E. Psychopathology of depression. Drugs Today (Barc), 2007, 43(10), 705-716.
244. Schiepers, O.J.; Wichers, M.C.; Maes, M. Cytokines and major depression. Prog Neuropsychopharmacol. Biol. Psychiatry, 2005, 29(2), 201-217.
245. Aihara, M.; Ida, I.; Yuuki, N.; Oshima, A.; Kumano, H.; Takahashi, K.; Fukuda, M.; Oriuchi, N.; Endo, K.; Matsuda, H.; Mikuni, M. HPA axis dysfunction in unmedicated major depressive disorder and its normalization by pharmacotherapy correlates with alteration of neural activity in prefrontal cortex and limbic/paralimbic regions. Psychiatry Res., 2007, 155(3), 245-256.
246. Holsboer, F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology, 2000, 23(5), 477-501.
247. Pariante, C.M.; Miller, A.H. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol. Psychiatry, 2001, 49(5), 391-404.
248. Claes, S. Glucocorticoid receptor polymorphisms in major depression. Ann. N. Y. Acad. Sci., 2009, 1179, 216-228.
249. Sapolsky, R.M.; Plotsky, P.M. Hypercortisolism and its possible neural bases. Biol. Psychiatry, 1990, 27(9), 937-952.
250. Elenkov, I.J. Glucocorticoids and the Th1/Th2 balance. Ann. N. Y. Acad. Sci., 2004, 1024, 138-146.
251. Pavon, L.; Sandoval-Lopez, G.; Eugenia Hernandez, M.; Loria, F.; Estrada, I.; Perez, M.; Moreno, J.; Avila, U.; Leff, P.; Anton, B.; Heinze, G. Th2 cytokine response in Major Depressive Disorder patients before treatment. J. Neuroimmunol., 2006, 172(1-2), 156-165.
252. Hernandez, M.E.; Mendieta, D.; Martinez-Fong, D.; Loria, F.; Moreno, J.; Estrada, I.; Bojalil, R.; Pavon, L. Variations in circulating cytokine levels during 52 week course of treatment with SSRI for major depressive disorder. Eur. Neuropsychopharmacol., 2008, 18(12), 917-924.
253. Legros, S.; Mendlewicz, J.; Wybran, J. Immunoglobulins, autoantibodies and other serum protein fractions in psychiatric disorders. Eur. Arch. Psychiatry Neurol. Sci., 1985, 235(1), 9-11.
254. Zorrilla, E.P.; Luborsky, L.; McKay, J.R.; Rosenthal, R.; Houldin, A.; Tax, A.; McCorkle, R.; Seligman, D.A.; Schmidt, K. The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav. Immun., 2001, 15(3), 199-226.
255. Cohen, S.; Janicki-Deverts, D.; Miller, G.E. Psychological stress and disease. JAMA, 2007, 298(14), 1685-1687.
256. Lopez, J.F.; Chalmers, D.T.; Little, K.Y.; Watson, S.J. A.E. Bennett Research Award. Regulation of serotonin1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression. Biol. Psychiatry, 1998, 43(8), 547-573.
257. Gorman, J.M.; Docherty, J.P. A hypothesized role for dendritic remodeling in the etiology of mood and anxiety disorders. J. Neuropsychiatry Clin. Neurosci., 2010, 22(3), 256-264.
258. Fernandez, S.P.; Gaspar, P. Investigating anxiety and depressivelike phenotypes in genetic mouse models of serotonin depletion. Neuropharmacology, 2012, 62(1), 144-154.
259. Gill, J.; Vythilingam, M.; Page, G.G. Low cortisol, high DHEA, and high levels of stimulated TNF-alpha, and IL-6 in women with PTSD. J. Trauma Stress, 2008, 21(6), 530-539.
260. Sutherland, A.G.; Alexander, D.A.; Hutchison, J.D. Disturbance of pro-inflammatory cytokines in post-traumatic psychopathology. Cytokine, 2003, 24(5), 219-225.
261. Konuk, N.; Tekin, I.O.; Ozturk, U.; Atik, L.; Atasoy, N.; Bektas, S.; Erdogan, A. Plasma levels of tumor necrosis factor-alpha and interleukin-6 in obsessive compulsive disorder. Mediat. Inflamm., 2007, 2007, 65704.
262. Rook, G.A.; Zumla, A. Gulf War syndrome: is it due to a systemic shift in cytokine balance towards a Th2 profile? Lancet, 1997, 349(9068), 1831-1833.
263. Cramer, A.O.; Waldorp, L.J.; van der Maas, H.L.; Borsboom, D. Comorbidity: a network perspective. Behav. Brain Sci., 2010, 33(2-3), 137-150; discussion 150-193.
264. Boden, J.M.; Fergusson, D.M.; Horwood, L.J. Cigarette smoking and depression: tests of causal linkages using a longitudinal birth cohort. Br. J. Psychiatry, 2010, 196(6), 440-446.
265. Coryell, W.; Young, E.; Carroll, B. Hyperactivity of the hypothalamic-pituitary-adrenal axis and mortality in major depressive disorder. Psychiatry Res., 2006, 142(1), 99-104.
266. Vgontzas, A.N.; Papanicolaou, D.A.; Bixler, E.O.; Hopper, K.; Lotsikas, A.; Lin, H.M.; Kales, A.; Chrousos, G.P. Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia. J. Clin. Endocrinol. Metab., 2000, 85(3), 1151-1158.
267. Maes, M. Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2011, 35(3), 664-75.
268. Gabbay, V.; Klein, R.G.; Alonso, C.M.; Babb, J.S.; Nishawala, M.; De Jesus, G.; Hirsch, G.S.; Hottinger-Blanc, P.M.; Gonzalez, C.J. Immune system dysregulation in adolescent major depressive disorder. J. Affect. Disord., 2009, 115(1-2), 177-182.
269. Wong, M.L.; Kling, M.A.; Munson, P.J.; Listwak, S.; Licinio, J.; Prolo, P.; Karp, B.; McCutcheon, I.E.; Geracioti, T.D., Jr.; DeBellis, M.D.; Rice, K.C.; Goldstein, D.S.; Veldhuis, J.D.; Chrousos, G.P.; Oldfield, E.H.; McCann, S.M.; Gold, P.W. Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone. Proc. Natl. Acad. Sci. U. S. A., 2000, 97(1), 325-330.
270. Gold, P.W.; Chrousos, G.P. The endocrinology of melancholic and atypical depression: relation to neurocircuitry and somatic consequences. Proc. Assoc. Am. Phys., 1999, 111(1), 22-34.
271. Gold, P.W.; Chrousos, G.P. Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states. Mol. Psychiatry, 2002, 7(3), 254-275.
272. Perugi, G.; Fornaro, M.; Akiskal, H.S. Are atypical depression, borderline personality disorder and bipolar II disorder overlapping manifestations of a common cyclothymic diathesis? World Psychiatry, 2011, 10(1), 45-51.
273. Brietzke, E.; Stertz, L.; Fernandes, B.S.; Kauer-Sant'anna, M.; Mascarenhas, M.; Escosteguy Vargas, A.; Chies, J.A.; Kapczinski, F. Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J. Affect. Disord., 2009, 116(3), 214-217.
274. Liu, H.C.; Yang, Y.Y.; Chou, Y.M.; Chen, K.P.; Shen, W.W.; Leu, S.J. Immunologic variables in acute mania of bipolar disorder. J. Neuroimmunol., 2004, 150(1-2), 116-122.
275. Kunz, M.; Cereser, K.M.; Goi, P.D.; Fries, G.R.; Teixeira, A.L.; Fernandes, B.S.; Belmonte-de-Abreu, P.S.; Kauer-Sant'anna, M.; Kapczinski, F.; Gama, C.S. Serum levels of IL-6, IL-10 and TNFalpha in patients with bipolar disorder and schizophrenia: differences in pro-and anti-inflammatory balance. Rev. Bras Psiquiatr., 2011, 33(3), 368-74.
276. Garver, D.L.; Tamas, R.L.; Holcomb, J.A. Elevated interleukin-6 in the cerebrospinal fluid of a previously delineated schizophrenia subtype. Neuropsychopharmacology, 2003, 28(8), 1515-1520.
277. Mittleman, B.B.; Castellanos, F.X.; Jacobsen, L.K.; Rapoport, J.L.; Swedo, S.E.; Shearer, G.M. Cerebrospinal fluid cytokines in pediatric neuropsychiatric disease. J. Immunol., 1997, 159(6), 2994-2999.
278. Liberzon, I.; King, A.P.; Britton, J.C.; Phan, K.L.; Abelson, J.L.; Taylor, S.F. Paralimbic and medial prefrontal cortical involvement in neuroendocrine responses to traumatic stimuli. Am. J. Psychiatry, 2007, 164(8), 1250-1258.
279. Cerullo, M.A.; Adler, C.M.; Delbello, M.P.; Strakowski, S.M. The functional neuroanatomy of bipolar disorder. Int. Rev. Psychiatry, 2009, 21(4), 314-322.
280. Fountoulakis, K.N.; Giannakopoulos, P.; Kovari, E.; Bouras, C. Assessing the role of cingulate cortex in bipolar disorder: neuropathological, structural and functional imaging data. Brain Res. Rev., 2008, 59(1), 9-21.
281. Chen, C.H.; Suckling, J.; Lennox, B.R.; Ooi, C.; Bullmore, E.T. A quantitative meta-analysis of fMRI studies in bipolar disorder. Bipolar Disord., 2011, 13(1), 1-15.
282. MacKinnon, D.F.; Zamoiski, R. Panic comorbidity with bipolar disorder: what is the manic-panic connection? Bipolar Disord., 2006, 8(6), 648-664.
283. Dedovic, K.; Duchesne, A.; Andrews, J.; Engert, V.; Pruessner, J.C. The brain and the stress axis: the neural correlates of cortisol regulation in response to stress. Neuroimage, 2009, 47(3), 864-871.
284. Kenis, G.; Maes, M. Effects of antidepressants on the production of cytokines. Int. J. Neuropsychopharmacol., 2002, 5(4), 401-412.
285. Basterzi, A.D.; Aydemir, C.; Kisa, C.; Aksaray, S.; Tuzer, V.; Yazici, K.; Goka, E. IL-6 levels decrease with SSRI treatment in patients with major depression. Hum. Psychopharmacol., 2005, 20(7), 473-476.
286. Diamond, M.; Kelly, J.P.; Connor, T.J. Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur. Neuropsychopharmacol., 2006, 16(7), 481-490.
287. Leo, R.; Di Lorenzo, G.; Tesauro, M.; Razzini, C.; Forleo, G.B.; Chiricolo, G.; Cola, C.; Zanasi, M.; Troisi, A.; Siracusano, A.; Lauro, R.; Romeo, F. Association between enhanced soluble CD40 ligand and proinflammatory and prothrombotic states in major depressive disorder: pilot observations on the effects of selective serotonin reuptake inhibitor therapy. J. Clin. Psychiatry, 2006, 67(11), 1760-1766.
288. Tsao, C.W.; Lin, Y.S.; Chen, C.C.; Bai, C.H.; Wu, S.R. Cytokines and serotonin transporter in patients with major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2006, 30(5), 899-905.
289. Nemeroff, C.B.; Owens, M.J. Pharmacologic differences among the SSRIs: focus on monoamine transporters and the HPA axis. CNS Spectr., 2004, 9(6 Suppl 4), 23-31.
290. Blardi, P.; De Lalla, A.; Leo, A.; Auteri, A.; Iapichino, S.; Di Muro, A.; Dell'Erba, A.; Castrogiovanni, P. Serotonin and fluoxetine levels in plasma and platelets after fluoxetine treatment in depressive patients. J. Clin. Psychopharmacol., 2002, 22(2), 131-136.
291. Castrogiovanni, P.; Blardi, P.; De Lalla, A.; Dell'Erba, A.; Auteri, A. Can serotonin and fluoxetine levels in plasma and platelets predict clinical response in depression? Psychopharmacol. Bull, 2003, 37(2), 102-108.
292. Blier, P. Pharmacology of rapid-onset antidepressant treatment strategies. J. Clin. Psychiatry, 2001, 62 Suppl 15, 12-17.
293. El Mansari, M.; Sanchez, C.; Chouvet, G.; Renaud, B.; Haddjeri, N. Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: an in vivo electrophysiological study in rat brain. Neuropsychopharmacology, 2005, 30(7), 1269-1277.
294. Hensler, J.G. Differential regulation of 5-HT1A receptor-G protein interactions in brain following chronic antidepressant administration. Neuropsychopharmacology, 2002, 26(5), 565-573.
295. Yamauchi, M.; Miyara, T.; Matsushima, T.; Imanishi, T. Desensitization of 5-HT2A receptor function by chronic administration of selective serotonin reuptake inhibitors. Brain Res., 2006, 1067(1), 164-169.
296. Yamauchi, M.; Tatebayashi, T.; Nagase, K.; Kojima, M.; Imanishi, T. Chronic treatment with fluvoxamine desensitizes 5-HT2C receptor-mediated hypolocomotion in rats. Pharmacol. Biochem. Behav., 2004, 78(4), 683-689.
297. Antonijevic, I.A. Depressive disorders--is it time to endorse different pathophysiologies? Psychoneuroendocrinology, 2006, 31(1), 1-15.
298. Nikisch, G.; Agren, H.; Eap, C.B.; Czernik, A.; Baumann, P.; Mathe, A.A. Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram. Int. J. Neuropsychopharmacol., 2005, 8(3), 403-410.
299. Papiol, S.; Arias, B.; Gasto, C.; Gutierrez, B.; Catalan, R.; Fananas, L. Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment. J. Affect Disord., 2007, 104(1-3), 83-90.
300. Taler, M.; Gil-Ad, I.; Lomnitski, L.; Korov, I.; Baharav, E.; Bar, M.; Zolokov, A.; Weizman, A. Immunomodulatory effect of selective serotonin reuptake inhibitors (SSRIs) on human T lymphocyte function and gene expression. Eur. Neuropsychopharmacol., 2007, 17(12), 774-780.
301. Padol, I.T.; Hunt, R.H. Association of myocardial infarctions with COX-2 inhibition may be related to immunomodulation towards a Th1 response resulting in atheromatous plaque instability: an evidence-based interpretation. Rheumatology (Oxford), 2010, 49(5), 837-843.
302. De Berardis, D.; Conti, C.M.; Serroni, N.; Moschetta, F.S.; Olivieri, L.; Carano, A.; Salerno, R.M.; Cavuto, M.; Farina, B.; Alessandrini, M.; Janiri, L.; Pozzi, G.; Di Giannantonio, M. The effect of newer serotonin-noradrenalin antidepressants on cytokine production: a review of the current literature. Int. J. Immunopathol. Pharmacol., 2010, 23(2), 417-422.
303. Kubera, M.; Lin, A.H.; Kenis, G.; Bosmans, E.; van Bockstaele, D.; Maes, M. Anti-Inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio. J. Clin. Psychopharmacol., 2001, 21(2), 199-206.
304. Lee, K.M.; Kim, Y.K. The role of IL-12 and TGF-beta1 in the pathophysiology of major depressive disorder. Int. Immunopharmacol., 2006, 6(8), 1298-1304.
305. Vollmar, P.; Haghikia, A.; Dermietzel, R.; Faustmann, P.M. Venlafaxine exhibits an anti-inflammatory effect in an inflammatory co-culture model. Int. J. Neuropsychopharmacol., 2008, 11(1), 111-117.
306. Vollmar, P.; Nessler, S.; Kalluri, S.R.; Hartung, H.P.; Hemmer, B. The antidepressant venlafaxine ameliorates murine experimental autoimmune encephalomyelitis by suppression of pro-inflammatory cytokines. Int. J. Neuropsychopharmacol., 2009, 12(4), 525-536.
307. Diehl, S.; Rincon, M. The two faces of IL-6 on Th1/Th2 differentiation. Mol. Immunol., 2002, 39(9), 531-536.
308. Piletz, J.E.; Halaris, A.; Iqbal, O.; Hoppensteadt, D.; Fareed, J.; Zhu, H.; Sinacore, J.; Lindsay Devane, C. Pro-inflammatory biomakers in depression: Treatment with venlafaxine. World J. Biol. Psychiatry, 2008, 1-11.
309. Kubera, M.; Kenis, G.; Bosmans, E.; Kajta, M.; Basta-Kaim, A.; Scharpe, S.; Budziszewska, B.; Maes, M. Stimulatory effect of antidepressants on the production of IL-6. Int. Immunopharmacol., 2004, 4(2), 185-192.
310. Beique, J.; de Montigny, C.; Blier, P.; Debonnel, G. Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: I. in vivo electrophysiological studies in the rat. Neuropharmacology, 2000, 39(10), 1800-1812.
311. Beique, J.; de Montigny, C.; Blier, P.; Debonnel, G. Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: II. In vitro studies in the rat. Neuropharmacology, 2000, 39(10), 1813-1822.
312. Nalepa, I.; Manier, D.H.; Gillespie, D.D.; Rossby, S.P.; Schmidt, D.E.; Sulser, F. Lack of beta adrenoceptor desensitization in brain following the dual noradrenaline and serotonin reuptake inhibitor venlafaxine. Eur. Neuropsychopharmacol., 1998, 8(3), 227-232.
313. Debonnel, G.; Saint-Andre, E.; Hebert, C.; de Montigny, C.; Lavoie, N.; Blier, P. Differential physiological effects of a low dose and high doses of venlafaxine in major depression. Int. J. Neuropsychopharmacol., 2007, 10(1), 51-61.
314. Trivedi, M.H.; Desaiah, D.; Ossanna, M.J.; Pritchett, Y.L.; Brannan, S.K.; Detke, M.J. Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine. Int. Clin. Psychopharmacol., 2008, 23(3), 161-169.
315. Rueter, L.E.; Kasamo, K.; de Montigny, C.; Blier, P. Effect of long-term administration of duloxetine on the function of serotonin and noradrenaline terminals in the rat brain. Naunyn Schmiedebergs Arch. Pharmacol., 1998, 357(6), 600-610.
316. Rueter, L.E.; De Montigny, C.; Blier, P. Electrophysiological characterization of the effect of long-term duloxetine administration on the rat serotonergic and noradrenergic systems. J. Pharmacol. Exp. Ther., 1998, 285(2), 404-412.
317. Invernizzi, R.W.; Garattini, S. Role of presynaptic alpha2-adrenoceptors in antidepressant action: recent findings from microdialysis studies. Prog Neuropsychopharmacol. Biol. Psychiatry, 2004, 28(5), 819-827.
318. Fornaro, M.; Martino, M.; Battaglia, F.; Colicchio, S.; Perugi, G. Increase in IL-6 levels among major depressive disorder patients after a 6-week treatment with duloxetine 60 mg/day: a preliminary observation. Neuropsychiatr. Dis. Treat., 2011, 7, 51-56.
319. McNamee, E.N.; Ryan, K.M.; Griffin, E.W.; Gonzalez-Reyes, R.E.; Ryan, K.J.; Harkin, A.; Connor, T.J. Noradrenaline acting at central beta-adrenoceptors induces interleukin-10 and suppressor of cytokine signaling-3 expression in rat brain: implications for neurodegeneration. Brain Behav. Immun., 2010, 24(4), 660-671.
320. McNamee, E.N.; Griffin, E.W.; Ryan, K.M.; Ryan, K.J.; Heffernan, S.; Harkin, A.; Connor, T.J. Noradrenaline acting at beta-adrenoceptors induces expression of IL-1beta and its negative regulators IL-1ra and IL-1RII, and drives an overall antiinflammatory phenotype in rat cortex. Neuropharmacology, 2010, 59(1-2), 37-48.
321. Hashioka, S.; Klegeris, A.; Monji, A.; Kato, T.; Sawada, M.; McGeer, P.L.; Kanba, S. Antidepressants inhibit interferongamma-induced microglial production of IL-6 and nitric oxide. Exp. Neurol., 2007, 206(1), 33-42.
322. O'Sullivan, J.B.; Ryan, K.M.; Curtin, N.M.; Harkin, A.; Connor, T.J. Noradrenaline reuptake inhibitors limit neuroinflammation in rat cortex following a systemic inflammatory challenge: implications for depression and neurodegeneration. Int. J. Neuropsychopharmacol., 2009, 12(5), 687-699.
323. Agelink, M.W.; Ullrich, H.; Baumann, B.; Strum, S.; Majewski, T. Effects of reboxetine, a selective norepinephrine reuptake inhibitor, on sympathetic and parasympathetic outflow to the heart: preliminary data. Psychopharmacology (Berl), 2002, 163(2), 151-156.
324. Parini, S.; Renoldi, G.; Battaglia, A.; Invernizzi, R.W. Chronic reboxetine desensitizes terminal but not somatodendritic alpha2-adrenoceptors controlling noradrenaline release in the rat dorsal hippocampus. Neuropsychopharmacology, 2005, 30(6), 1048-1055.
325. Rogoz, Z.; Margas, W.; Skuza, G.; Solich, J.; Kusmider, M.; Dziedzicka-Wasylewska, M. Effect of repeated treatment with reboxetine on the central alpha 1-adrenergic and dopaminergic receptors. Pol. J. Pharmacol., 2002, 54(6), 593-603.
326. Rogoz, Z.; Kolasiewicz, W. Effect of repeated treatment with reboxetine on the central alpha1-adrenergic system. Pol. J. Pharmacol., 2001, 53(6), 663-667.
327. Gould, G.G.; Pardon, M.C.; Morilak, D.A.; Frazer, A. Regulatory effects of reboxetine treatment alone, or following paroxetine treatment, on brain noradrenergic and serotonergic systems. Neuropsychopharmacology, 2003, 28(9), 1633-1641.
328. Holoubek, G.; Noldner, M.; Treiber, K.; Muller, W.E. Effect of chronic antidepressant treatment on beta-receptor coupled signal transduction cascade. Which effect matters most? Pharmacopsychiatry, 2004, 37 Suppl 2, S113-119.
329. Linner, L.; Endersz, H.; Ohman, D.; Bengtsson, F.; Schalling, M.; Svensson, T.H. Reboxetine modulates the firing pattern of dopamine cells in the ventral tegmental area and selectively increases dopamine availability in the prefrontal cortex. J. Pharmacol. Exp. Ther., 2001, 297(2), 540-546.
330. Page, M.E.; Lucki, I. Effects of acute and chronic reboxetine treatment on stress-induced monoamine efflux in the rat frontal cortex. Neuropsychopharmacology, 2002, 27(2), 237-247.
331. Szabo, S.T.; Blier, P. Effects of the selective norepinephrine reuptake inhibitor reboxetine on norepinephrine and serotonin transmission in the rat hippocampus. Neuropsychopharmacology, 2001, 25(6), 845-857.
332. Miller, D.K.; Wong, E.H.; Chesnut, M.D.; Dwoskin, L.P. Reboxetine: functional inhibition of monoamine transporters and nicotinic acetylcholine receptors. J. Pharmacol. Exp. Ther., 2002, 302(2), 687-695.
333. Tzavara, E.T.; Bymaster, F.P.; Overshiner, C.D.; Davis, R.J.; Perry, K.W.; Wolff, M.; McKinzie, D.L.; Witkin, J.M.; Nomikos, G.G. Procholinergic and memory enhancing properties of the selective norepinephrine uptake inhibitor atomoxetine. Mol. Psychiatry, 2006, 11(2), 187-195.
334. Schule, C.; Baghai, T.; Schmidbauer, S.; Bidlingmaier, M.; Strasburger, C.J.; Laakmann, G. Reboxetine acutely stimulates cortisol, ACTH, growth hormone and prolactin secretion in healthy male subjects. Psychoneuroendocrinology, 2004, 29(2), 185-200.
335. Schule, C.; Baghai, T.; Laakmann, G. Mirtazapine decreases stimulatory effects of reboxetine on cortisol, adrenocorticotropin and prolactin secretion in healthy male subjects. Neuroendocrinology, 2004, 79(1), 54-62.
336. Brustolim, D.; Ribeiro-dos-Santos, R.; Kast, R.E.; Altschuler, E.L.; Soares, M.B. A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice. Int. Immunopharmacol., 2006, 6(6), 903-907.
337. Eller, T.; Vasar, V.; Shlik, J.; Maron, E. Effects of bupropion augmentation on pro-inflammatory cytokines in escitalopramresistant patients with major depressive disorder. J. Psychopharmacol., 2009, 23(7), 854-858.
338. Stahl, S.M.; Pradko, J.F.; Haight, B.R.; Modell, J.G.; Rockett, C.B.; Learned-Coughlin, S. A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor. Prim. Care Companion J. Clin. Psychiatry, 2004, 6(4), 159-166.
339. Ferris, R.M.; Beaman, O.J. Bupropion: a new antidepressant drug, the mechanism of action of which is not associated with downregulation of postsynaptic beta-adrenergic, serotonergic (5-HT2), alpha 2-adrenergic, imipramine and dopaminergic receptors in brain. Neuropharmacology, 1983, 22(11), 1257-1267.
340. Arias, H.R. Is the inhibition of nicotinic acetylcholine receptors by bupropion involved in its clinical actions? Int. J. Biochem. Cell Biol., 2009, 41(11), 2098-2108.
341. Arias, H.R.; Gumilar, F.; Rosenberg, A.; Targowska-Duda, K.M.; Feuerbach, D.; Jozwiak, K.; Moaddel, R.; Wainer, I.W.; Bouzat, C. Interaction of bupropion with muscle-type nicotinic acetylcholine receptors in different conformational states. Biochemistry, 2009, 48(21), 4506-4518.
342. Kraus, T.; Haack, M.; Schuld, A.; Hinze-Selch, D.; Koethe, D.; Pollmacher, T. Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine. Pharmacopsychiatry, 2002, 35(6), 220-225.
343. Kubera, M.; Roman, A.; Basta-Kaim, A.; Budziszewska, B.; Zajicova, A.; Holan, V.; Rogoz, Z.; Skuza, G.; Leskiewicz, M.; Regulska, M.; Jagla, G.; Nowak, W.; Lason, W. Effect of acute and repeated treatment with mirtazapine on the immunity of noradrenaline transporter knockout C57BL/6J mice. Pharmacol. Biochem. Behav., 2006, 85(4), 813-819.
344. Anttila, S.A.; Leinonen, E.V. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev., 2001, 7(3), 249-264.
345. Haddjeri, N.; Blier, P.; de Montigny, C. Effects of long-term treatment with the alpha 2-adrenoceptor antagonist mirtazapine on 5-HT neurotransmission. Naunyn Schmiedebergs Arch. Pharmacol., 1997, 355(1), 20-29.
346. Haddjeri, N.; Blier, P.; de Montigny, C. Acute and long-term actions of the antidepressant drug mirtazapine on central 5-HT neurotransmission. J. Affect. Disord., 1998, 51(3), 255-266.
347. de Boer, T. The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int. Clin. Psychopharmacol., 1995, 10 Suppl 4, 19-23.
348. Kast, R.E. Anti-and pro-inflammatory considerations in antidepressant use during medical illness: bupropion lowers and mirtazapine increases circulating tumor necrosis factor-alpha levels. Gen. Hosp. Psychiatry, 2003, 25(6), 495-496.
349. Millan, M.J.; Gobert, A.; Rivet, J.M.; Adhumeau-Auclair, A.; Cussac, D.; Newman-Tancredi, A.; Dekeyne, A.; Nicolas, J.P.; Lejeune, F. Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur. J. Neurosci., 2000, 12(3), 1079-1095.
350. Schmid, D.A.; Wichniak, A.; Uhr, M.; Ising, M.; Brunner, H.; Held, K.; Weikel, J.C.; Sonntag, A.; Steiger, A. Changes of sleep architecture, spectral composition of sleep EEG, the nocturnal secretion of cortisol, ACTH, GH, prolactin, melatonin, ghrelin, and leptin, and the DEX-CRH test in depressed patients during treatment with mirtazapine. Neuropsychopharmacology, 2006, 31(4), 832-844.
351. Stahl, S.M. Mechanism of action of trazodone: a multifunctional drug. CNS Spectr., 2009, 14(10), 536-546.
352. Shen, K.P.; Lo, Y.C.; Yang, R.C.; Liu, H.W.; Chen, I.J.; Wu, B.N. Antioxidant eugenosedin-A protects against lipopolysaccharideinduced hypotension, hyperglycaemia and cytokine immunoreactivity in rats and mice. J. Pharm. Pharmacol., 2005, 57(1), 117-125.
353. Maestro, S.; Casella, C.; Milone, A.; Muratori, F.; Palacio-Espasa, F. Study of the onset of autism through home movies. Psychopathology, 1999, 32(6), 292-300.
354. San, L.; Arranz, B. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. Eur. Psychiatry, 2008, 23(6), 396-402.
355. Carrillo-Vico, A.; Garcia-Maurino, S.; Calvo, J.R.; Guerrero, J.M. Melatonin counteracts the inhibitory effect of PGE2 on IL-2 production in human lymphocytes via its mt1 membrane receptor. FASEB J, 2003, 17(6), 755-757.
356. Leproult, R.; Van Onderbergen, A.; L'Hermite-Baleriaux, M.; Van Cauter, E.; Copinschi, G. Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men. Clin. Endocrinol. (Oxf), 2005, 63(3), 298-304.
357. Hanoun, N.; Mocaer, E.; Boyer, P.A.; Hamon, M.; Lanfumey, L. Differential effects of the novel antidepressant agomelatine (S 20098) versus fluoxetine on 5-HT1A receptors in the rat brain. Neuropharmacology, 2004, 47(4), 515-526.
358. Ying, S.W.; Rusak, B.; Mocaer, E. Chronic exposure to melatonin receptor agonists does not alter their effects on suprachiasmatic nucleus neurons. Eur. J. Pharmacol., 1998, 342(1), 29-37.
359. Xia, Z.; DePierre, J.W.; Nassberger, L. Tricyclic antidepressants inhibit IL-6, IL-1 beta and TNF-alpha release in human blood monocytes and IL-2 and interferon-gamma in T cells. Immunopharmacology, 1996, 34(1), 27-37.
360. Braeckman, L.; De Bacquer, D.; Maes, L.; De Backer, G. Effects of a low-intensity worksite-based nutrition intervention. Occup. Med. (Lond), 1999, 49(8), 549-555.
361. Huang, Y.Y.; Peng, C.H.; Yang, Y.P.; Wu, C.C.; Hsu, W.M.; Wang, H.J.; Chan, K.H.; Chou, Y.P.; Chen, S.J.; Chang, Y.L. Desipramine activated Bcl-2 expression and inhibited lipopolysaccharide-induced apoptosis in hippocampus-derived adult neural stem cells. J. Pharmacol. Sci., 2007, 104(1), 61-72.
362. Tai, Y.H.; Wang, Y.H.; Wang, J.J.; Tao, P.L.; Tung, C.S.; Wong, C.S. Amitriptyline suppresses neuroinflammation and up-regulates glutamate transporters in morphine-tolerant rats. Pain, 2006, 124(1-2), 77-86.
363. Budziszewska, B.; Basta-Kaim, A.; Kubera, M.; Jaworska, L.; Leskiewicz, M.; Tetich, M.; Otczyk, M.; Zajicova, A.; Holan, V.; Lason, W. Effect of lipopolysaccharide and antidepressant drugs on glucocorticoid receptor-mediated gene transcription. Pharmacol. Rep., 2005, 57(4), 540-544.
364. Wang, W.; Danielsson, A.; Svanberg, E.; Lundholm, K. Lack of effects by tricyclic antidepressant and serotonin inhibitors on anorexia in MCG 101 tumor-bearing mice with eicosanoid-related cachexia. Nutrition, 2003, 19(1), 47-53.
365. Stahl, S.M. Basic psychopharmacology of antidepressants, part 1: Antidepressants have seven distinct mechanisms of action. J. Clin. Psychiatry, 1998, 59 Suppl 4, 5-14.
366. Shen, Y.; Connor, T.J.; Nolan, Y.; Kelly, J.P.; Leonard, B.E. Differential effect of chronic antidepressant treatments on lipopolysaccharide-induced depressive-like behavioural symptoms in the rat. Life Sci., 1999, 65(17), 1773-1786.
367. Ekuni, D.; Firth, J.D.; Nayer, T.; Tomofuji, T.; Sanbe, T.; Irie, K.; Yamamoto, T.; Oka, T.; Liu, Z.; Vielkind, J.; Putnins, E.E. Lipopolysaccharide-induced epithelial monoamine oxidase mediates alveolar bone loss in a rat chronic wound model. Am. J. Pathol., 2009, 175(4), 1398-1409.
368. Lin, A.; Song, C.; Kenis, G.; Bosmans, E.; De Jongh, R.; Scharpe, S.; Maes, M. The in vitro immunosuppressive effects of moclobemide in healthy volunteers. J. Affect. Disord., 2000, 58(1), 69-74.
369. Muller, T.; Kuhn, W.; Kruger, R.; Przuntek, H. Selegiline as immunostimulant--a novel mechanism of action? J. Neural. Transm. Suppl., 1998, 52, 321-328.
370. Garrick, N.A.; Scheinin, M.; Chang, W.H.; Linnoila, M.; Murphy, D.L. Differential effects of clorgyline on catecholamine and indoleamine metabolites in the cerebrospinal fluid of rhesus monkeys. Biochem. Pharmacol., 1984, 33(9), 1423-1427.
371. Gerlach, M.; Youdim, M.B.; Riederer, P. Pharmacology of selegiline. Neurology, 1996, 47(6 Suppl 3), S137-145.
372. Kast, R.E.; Altschuler, E.L. Remission of Crohn's disease on bupropion. Gastroenterology, 2001, 121(5), 1260-1261.
373. Kane, S.; Altschuler, E.L.; Kast, R.E. Crohn's disease remission on bupropion. Gastroenterology, 2003, 125(4), 1290.
374. Kast, R.E. Crohn's disease remission with phenelzine treatment. Gastroenterology, 1998, 115(4), 1034-1035.
375. Scott, M.A.; Letrent, K.J.; Hager, K.L.; Burch, J.L. Use of transdermal amitriptyline gel in a patient with chronic pain and depression. Pharmacotherapy, 1999, 19(2), 236-239.
376. Mikocka-Walus, A.A.; Turnbull, D.A.; Moulding, N.T.; Wilson, I.G.; Andrews, J.M.; Holtmann, G.J. Antidepressants and inflammatory bowel disease: a systematic review. Clin. Pract. Epidemiol. Ment. Health, 2006, 2, 24.
377. Torras B.M.T.; Pardo, F.C.; Bernad, G. J.A.; Roig, G.I.; Pedregosa, D.M.M.; Plans, S.E. Three cases of intestinal inflammatory disease caused by anti-depressant treatment with paroxetine. Aten Primaria, 2003, 31(2), 135.
378. Modell, J.G.; Boyce, S.; Taylor, E.; Katholi, C. Treatment of atopic dermatitis and psoriasis vulgaris with bupropion-SR: a pilot study. Psychosom. Med., 2002, 64(5), 835-840.
379. Alpsoy, E.; Ozcan, E.; Cetin, L.; Ozgur, O.; Er, H.; Yilmaz, E.; Karaman, T. Is the efficacy of topical corticosteroid therapy for psoriasis vulgaris enhanced by concurrent moclobemide therapy? A double-blind, placebo-controlled study. J. Am. Acad. Dermatol., 1998, 38(2 Pt 1), 197-200.
380. Gupta, M.A.; Gupta, A.K. The use of psychotropic drugs in dermatology. Dermatol. Clin., 2000, 18(4), 711-725, x.
381. Osborne, S.F.; Stafford, L.; Orr, K.G. Paroxetine-associated psoriasis. Am. J. Psychiatry, 2002, 159(12), 2113.
382. Tamer, E.; Gur, G.; Polat, M.; Alli, N. Flare-up of pustular psoriasis with fluoxetine: possibility of a serotoninergic influence? J. Dermatol. Treat, 2009, 20(3), 1-3.
383. Wagena, E.J.; Huibers, M.J.; van Schayck, C.P. Antidepressants in the treatment of patients with COPD: possible associations between smoking cigarettes, COPD and depression. Thorax, 2001, 56(8), 587-588.
384. Borson, S.; McDonald, G.J.; Gayle, T.; Deffebach, M.; Lakshminarayan, S.; VanTuinen, C. Improvement in mood, physical symptoms, and function with nortriptyline for depression in patients with chronic obstructive pulmonary disease. Psychosomatics, 1992, 33(2), 190-201.
385. Smoller, J.W.; Otto, M.W. Panic, dyspnea, and asthma. Curr. Opin. Pulm. Med., 1998, 4(1), 40-45.
386. Brown, E.S.; Vigil, L.; Khan, D.A.; Liggin, J.D.; Carmody, T.J.; Rush, A.J. A randomized trial of citalopram versus placebo in outpatients with asthma and major depressive disorder: a proof of concept study. Biol. Psychiatry, 2005, 58(11), 865-870.
387. Nardi, A.E. Where are the guidelines for the treatment of asthma with panic spectrum symptoms? Am. J. Respir. Crit. Care Med, 2005, 172(8), 1055-1056; author reply 1056.
388. Melien, O.; Skaali, T.; Myhr, K.; Brors, O. Venlafaxine and asthma. Nord. J. Psychiatry, 2005, 59(6), 538-540.
389. DeKruyff, R.H.; Fang, Y.; Umetsu, D.T. Corticosteroids enhance the capacity of macrophages to induce Th2 cytokine synthesis in CD4+ lymphocytes by inhibiting IL-12 production. J. Immunol., 1998, 160(5), 2231-2237.
390. Bolden-Watson, C.; Richelson, E. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci., 1993, 52(12), 1023-1029.
391. Loder, C.; Allawi, J.; Horrobin, D.F. Treatment of multiple sclerosis with lofepramine, L-phenylalanine and vitamin B(12): mechanism of action and clinical importance: roles of the locus coeruleus and central noradrenergic systems. Med. Hypotheses, 2002, 59(5), 594-602.
392. Puri, B.K.; Bydder, G.M.; Chaudhuri, K.R.; Al Saffar, B.Y.; Curati, W.L.; White, S.J.; Mitchell, L.; Hajnal, J.V.; Horrobin, D.F. MRI changes in multiple sclerosis following treatment with lofepramine and L-phenylalanine. Neuroreport, 2001, 12(9), 1821-1824.
393. Altschuler, E.L. Monoamine oxidase inhibitors in rheumatoid arthritis-anti-tumor necrosis factor? Int. J. Immunopharmacol., 2000, 22(11), 1007-1008.
394. Lieb, J. Remission of rheumatoid arthritis and other disorders of immunity in patients taking monoamine oxidase inhibitors. Int. J. Immunopharmacol., 1983, 5(4), 353-357.
395. Sacre, S.; Medghalchi, M.; Gregory, B.; Brennan, F.; Williams, R. Fluoxetine and citalopram exhibit potent antiinflammatory activity in human and murine models of rheumatoid arthritis and inhibit toll-like receptors. Arthritis Rheum., 2010, 62(3), 683-693.
396. Altschuler, E.L. Phenelzine as adjuvant treatment for Behcet's disease? Int. J. Dermatol., 1999, 38(12), 955.
397. Altschuler, E.L. Monoamine oxidase inhibitors for IgA nephropathy. Med. Hypotheses, 2001, 56(2), 225-226.
398. Chavant, F.; Deguil, J.; Pain, S.; Ingrand, I.; Milin, S.; Fauconneau, B.; Perault-Pochat, M.C.; Lafay-Chebassier, C. Imipramine, in part through tumor necrosis factor alpha inhibition, prevents cognitive decline and beta-amyloid accumulation in a mouse model of Alzheimer's disease. J. Pharmacol. Exp. Ther., 2010, 332(2), 505-514.
399. Nelson, R.L.; Guo, Z.; Halagappa, V.M.; Pearson, M.; Gray, A.J.; Matsuoka, Y.; Brown, M.; Martin, B.; Iyun, T.; Maudsley, S.; Clark, R.F.; Mattson, M.P. Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice. Exp. Neurol., 2007, 205(1), 166-176.
400. Mowla, A.; Mosavinasab, M.; Pani, A. Does fluoxetine have any effect on the cognition of patients with mild cognitive impairment? A double-blind, placebo-controlled, clinical trial. J. Clin. Psychopharmacol., 2007, 27(1), 67-70.
401. Ekdahl, C.T.; Claasen, J.H.; Bonde, S.; Kokaia, Z.; Lindvall, O. Inflammation is detrimental for neurogenesis in adult brain. Proc. Natl. Acad. Sci. U. S. A., 2003, 100(23), 13632-13637.
402. Chung, Y.C.; Kim, S.R.; Jin, B.K. Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease. J. Immunol., 2010, 185(2), 1230-1237.
403. Thomas, T.; Bhavnani, B.R.; Thomas, P. Inhibition of human LDL oxidation by the neuroprotective drug l-deprenyl. Neurol. Res., 2002, 24(2), 169-173.
404. Galvani, S.; Coatrieux, C.; Elbaz, M.; Grazide, M.H.; Thiers, J.C.; Parini, A.; Uchida, K.; Kamar, N.; Rostaing, L.; Baltas, M.; Salvayre, R.; Negre-Salvayre, A. Carbonyl scavenger and antiatherogenic effects of hydrazine derivatives. Free Radic. Biol. Med., 2008, 45(10), 1457-1467.
405. Paslakis, G.; Gilles, M.; Lederbogen, F.; Schilling, C.; Scharnholz, B.; Deuschle, M. The effect of a 4-week treatment with reboxetine on metabolic parameters of depressed inpatients. Eur. Arch. Psychiatry Clin. Neurosci., 2011, 261(3), 173-177.
406. Levkovitz, Y.; Ben-Shushan, G.; Hershkovitz, A.; Isaac, R.; Gil-Ad, I.; Shvartsman, D.; Ronen, D.; Weizman, A.; Zick, Y. Antidepressants induce cellular insulin resistance by activation of IRS-1 kinases. Mol. Cell Neurosci., 2007, 36(3), 305-312.
407. Raeder, M.B.; Bjelland, I.; Emil Vollset, S.; Steen, V.M. Obesity, dyslipidemia, and diabetes with selective serotonin reuptake inhibitors: the Hordaland Health Study. J. Clin. Psychiatry, 2006, 67(12), 1974-1982.
408. Aviram, M.; Cogan, U.; Mokady, S. Excessive dietary tryptophan enhances plasma lipid peroxidation in rats. Atherosclerosis, 1991, 88(1), 29-34.
409. Kopf, D.; Westphal, S.; Luley, C.W.; Ritter, S.; Gilles, M.; Weber-Hamann, B.; Lederbogen, F.; Lehnert, H.; Henn, F.A.; Heuser, I.; Deuschle, M. Lipid metabolism and insulin resistance in depressed patients: significance of weight, hypercortisolism, and antidepressant treatment. J. Clin. Psychopharmacol., 2004, 24(5), 527-531.
410. Cardinali, D.P.; Cano, P.; Jimenez-Ortega, V.; Esquifino, A.I. Melatonin and the metabolic syndrome: physiopathologic and therapeutical implications. Neuroendocrinology, 2011, 93(3), 133-142.
411. Taylor, D. Antidepressant drugs and cardiovascular pathology: a clinical overview of effectiveness and safety. Acta Psychiatr. Scand., 2008, 118(6), 434-442.
412. Roose, S.P.; Laghrissi-Thode, F.; Kennedy, J.S.; Nelson, J.C.; Bigger, J.T., Jr.; Pollock, B.G.; Gaffney, A.; Narayan, M.; Finkel, M.S.; McCafferty, J.; Gergel, I. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA, 1998, 279(4), 287-291.
413. Regan, K.L. Depression treatment with selective serotonin reuptake inhibitors for the postacute coronary syndrome population: a literature review. J. Cardiovasc. Nurs., 2008, 23(6), 489-496.
414. Somberg, T.C.; Arora, R.R. Depression and heart disease: therapeutic implications. Cardiology, 2008, 111(2), 75-81.
415. Jiang, W.; Davidson, J.R. Antidepressant therapy in patients with ischemic heart disease. Am. Heart J., 2005, 150(5), 871-881.
416. George, A.K.; Kunwar, A.R.; Awasthi, A. Acute myocardial infarction in a young male on methylphenidate, bupropion, and erythromycin. J. Child Adolesc. Psychopharmacol., 2005, 15(4), 693-695.
417. Pederson, K.J.; Kuntz, D.H.; Garbe, G.J. Acute myocardial ischemia associated with ingestion of bupropion and pseudoephedrine in a 21-year-old man. Can. J. Cardiol., 2001, 17(5), 599-601.
418. Patterson, R.N.; Herity, N.A. Acute myocardial infarction following bupropion (Zyban). QJM, 2002, 95(1), 58-59.
419. Tousoulis, D.; Drolias, A.; Antoniades, C.; Vasiliadou, C.; Marinou, K.; Latsios, G.; Stefanadi, E.; Gounari, P.; Siasos, G.; Papageorgiou, N.; Trikas, A.; Stefanadis, C. Antidepressive treatment as a modulator of inflammatory process in patients with heart failure: effects on proinflammatory cytokines and acute phase protein levels. Int. J. Cardiol., 2009, 134(2), 238-243.
420. Zittel, S.; Weiller, C.; Liepert, J. Reboxetine improves motor function in chronic stroke. A pilot study. J. Neurol., 2007, 254(2), 197-201.
421. Wang, L.E.; Fink, G.R.; Diekhoff, S.; Rehme, A.K.; Eickhoff, S.B.; Grefkes, C. Noradrenergic enhancement improves motor network connectivity in stroke patients. Ann. Neurol., 2011, 69(2), 375-388.
422. Foster, D.J.; Good, D.C.; Fowlkes, A.; Sawaki, L. Atomoxetine enhances a short-term model of plasticity in humans. Arch. Phys. Med. Rehabil., 2006, 87(2), 216-221.
423. Goldstein, L.B. Effects of amphetamines and small related molecules on recovery after stroke in animals and man. Neuropharmacology, 2000, 39(5), 852-859.
424. Rampello, L.; Alvano, A.; Chiechio, S.; Raffaele, R.; Vecchio, I.; Malaguarnera, M. An evaluation of efficacy and safety of reboxetine in elderly patients affected by "retarded" post-stroke depression. A random, placebo-controlled study. Arch. Gerontol. Geriatr, 2005, 40(3), 275-285.
425. Kucukalic, A.; Bravo-Mehmedbasic, A.; Kulenovic, A.D.; Suljic-Mehmedika, E. Venlafaxine efficacy and tolerability in the treatment of post-stroke depression. Psychiatr. Danub, 2007, 19(1-2), 56-60.
426. Sivenius, J.; Sarasoja, T.; Aaltonen, H.; Heinonen, E.; Kilkku, O.; Reinikainen, K. Selegiline treatment facilitates recovery after stroke. Neurorehabil. Neural Repair, 2001, 15(3), 183-190.
427. Starkstein, S.E.; Mizrahi, R.; Power, B.D. Antidepressant therapy in post-stroke depression. Expert Opin. Pharmacother., 2008, 9(8), 1291-1298.
428. Benton, T.; Lynch, K.; Dube, B.; Gettes, D.R.; Tustin, N.B.; Ping Lai, J.; Metzger, D.S.; Blume, J.; Douglas, S.D.; Evans, D.L. Selective serotonin reuptake inhibitor suppression of HIV infectivity and replication. Psychosom. Med., 2010, 72(9), 925-932.
429. Evans, D.L.; Lynch, K.G.; Benton, T.; Dube, B.; Gettes, D.R.; Tustin, N.B.; Lai, J.P.; Metzger, D.; Douglas, S.D. Selective serotonin reuptake inhibitor and substance P antagonist enhancement of natural killer cell innate immunity in human immunodeficiency virus/acquired immunodeficiency syndrome. Biol. Psychiatry, 2008, 63(9), 899-905.
430. Ances, B.M.; Letendre, S.L.; Alexander, T.; Ellis, R.J. Role of psychiatric medications as adjunct therapy in the treatment of HIV associated neurocognitive disorders. Int. Rev. Psychiatry, 2008, 20(1), 89-93.
431. Cettomai, D.; McArthur, J.C. Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy. Arch Neurol., 2009, 66(2), 255-258.
432. Lanzafame, M.; Ferrari, S.; Lattuada, E.; Corsini, F.; Deganello, R.; Vento, S.; Concia, E. Mirtazapine in an HIV-1 infected patient with progressive multifocal leukoencephalopathy. Infez. Med., 2009, 17(1), 35-37.
433. Butterweck, V.; Bockers, T.; Korte, B.; Wittkowski, W.; Winterhoff, H. Long-term effects of St. John's wort and hypericin on monoamine levels in rat hypothalamus and hippocampus. Brain Res., 2002, 930(1-2), 21-29.
434. Miskovsky, P. Hypericin--a new antiviral and antitumor photosensitizer: mechanism of action and interaction with biological macromolecules. Curr. Drug Targets, 2002, 3(1), 55-84.
435. Czub, S.; Koutsilieri, E.; Sopper, S.; Czub, M.; Stahl-Hennig, C.; Muller, J.G.; Pedersen, V.; Gsell, W.; Heeney, J.L.; Gerlach, M.; Gosztonyi, G.; Riederer, P.; ter Meulen, V. Enhancement of central nervous system pathology in early simian immunodeficiency virus infection by dopaminergic drugs. Acta Neuropathol., 2001, 101(2), 85-91.
436. Czub, S.; Czub, M.; Koutsilieri, E.; Sopper, S.; Villinger, F.; Muller, J.G.; Stahl-Hennig, C.; Riederer, P.; Ter Meulen, V.; Gosztonyi, G. Modulation of simian immunodeficiency virus neuropathology by dopaminergic drugs. Acta Neuropathol., 2004, 107(3), 216-226.
437. Sockalingam, S.; Abbey, S.E. Managing depression during hepatitis C treatment. Can. J. Psychiatry, 2009, 54(9), 614-625.
438. Stauber, R.E.; Stadlbauer, V. Novel approaches for therapy of chronic hepatitis C. J. Clin. Virol., 2006, 36(2), 87-94.
439. Coogan, P.F.; Strom, B.L.; Rosenberg, L. Antidepressant use and colorectal cancer risk. Pharmacoepidemiol. Drug Saf., 2009, 18(11), 1111-1114.
440. Gil-Ad, I.; Zolokov, A.; Lomnitski, L.; Taler, M.; Bar, M.; Luria, D.; Ram, E.; Weizman, A. Evaluation of the potential anti-cancer activity of the antidepressant sertraline in human colon cancer cell lines and in colorectal cancer-xenografted mice. Int. J. Oncol., 2008, 33(2), 277-286.
441. Xu, W.; Tamim, H.; Shapiro, S.; Stang, M.R.; Collet, J.P. Use of antidepressants and risk of colorectal cancer: a nested case-control study. Lancet Oncol., 2006, 7(4), 301-308.
442. Toh, S.; Rodriguez, L.A.; Hernandez-Diaz, S. Use of antidepressants and risk of lung cancer. Cancer Causes Control, 2007, 18(10), 1055-1064.
443. Amit, B.H.; Gil-Ad, I.; Taler, M.; Bar, M.; Zolokov, A.; Weizman, A. Proapoptotic and chemosensitizing effects of selective serotonin reuptake inhibitors on T cell lymphoma/leukemia (Jurkat) in vitro. Eur. Neuropsychopharmacol., 2009, 19(10), 726-734.
444. Serafeim, A.; Holder, M.J.; Grafton, G.; Chamba, A.; Drayson, M.T.; Luong, Q.T.; Bunce, C.M.; Gregory, C.D.; Barnes, N.M.; Gordon, J. Selective serotonin reuptake inhibitors directly signal for apoptosis in biopsy-like Burkitt lymphoma cells. Blood, 2003, 101(8), 3212-3219.
445. Cloonan, S.M.; Drozgowska, A.; Fayne, D.; Williams, D.C. The antidepressants maprotiline and fluoxetine have potent selective antiproliferative effects against Burkitt lymphoma independently of the norepinephrine and serotonin transporters. Leuk. Lymphoma, 2010, 51(3), 523-539.
446. Ashbury, J.E.; Levesque, L.E.; Beck, P.A.; Aronson, K.J. A population-based case-control study of Selective Serotonin Reuptake Inhibitors (SSRIs) and breast cancer: the impact of duration of use, cumulative dose and latency. BMC Med., 2010, 8, 90.
447. Chien, C.; Li, C.I.; Heckbert, S.R.; Malone, K.E.; Boudreau, D.M.; Daling, J.R. Antidepressant use and breast cancer risk. Breast Cancer Res Treat., 2006, 95(2), 131-140.
448. Lash, T.L.; Cronin-Fenton, D.; Ahern, T.P.; Rosenberg, C.L.; Lunetta, K.L.; Silliman, R.A.; Hamilton-Dutoit, S.; Garne, J.P.; Ewertz, M.; Sorensen, H.T.; Pedersen, L. Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen. Acta Oncol., 2010, 49(3), 305-312.
449. Kast, R.E.; Altschuler, E.L. Co-administration of ramelton and fluvoxamine to increase levels of interleukin-2. Med. Hypotheses, 2006, 67(6), 1389-1390.
450. Hwang, M.S.; Yum, Y.N.; Joo, J.H.; Kim, S.; Lee, K.K.; Gee, S.W.; Kang, H.I.; Kim, O.H. Inhibition of c-erbB-2 expression an activity in human ovarian carcinoma cells by hypericin. Anticancer Res., 2001, 21(4A), 2649-2655.
451. Riechelmann, R.P.; Burman, D.; Tannock, I.F.; Rodin, G.; Zimmermann, C. Phase II trial of mirtazapine for cancer-related cachexia and anorexia. Am. J. Hosp. Palliat. Care, 2010, 27(2), 106-110.
452. Jia, L.; Shang, Y.Y.; Li, Y.Y. Effect of antidepressants on body weight, ethology and tumor growth of human pancreatic carcinoma xenografts in nude mice. World J. Gastroenterol., 2008, 14(27), 4377-4382.
453. Kast, R.E. Profound blockage of CXCR4 signaling at multiple points using the synergy between plerixafor, mirtazapine, and clotrimazole as a new glioblastoma treatment adjunct. Turk. Neurosurg., 2010, 20(4), 425-429.
454. Pan, C.C.; Cheng, H.H.; Huang, C.J.; Lu, Y.C.; Chen, I.S.; Liu, S.I.; Hsu, S.S.; Chang, H.T.; Huang, J.K.; Chen, J.S.; Jan, C.R. The antidepressant mirtazapine-induced cytosolic Ca2+ elevation and cytotoxicity in human osteosarcoma cells. Chin. J. Physiol., 2006, 49(6), 290-297.
455. Roberts, J.E.; Wiechmann, A.F.; Hu, D.N. Melatonin receptors in human uveal melanocytes and melanoma cells. J. Pineal Res., 2000, 28(3), 165-171.
456. Kubera, M.; Grygier, B.; Arteta, B.; Urbanska, K.; Basta-Kaim, A.; Budziszewska, B.; Leskiewicz, M.; Kolaczkowska, E.; Maes, M.; Szczepanik, M.; Majewska, M.; Lason, W. Age-dependent stimulatory effect of desipramine and fluoxetine pretreatment on metastasis formation by B16F10 melanoma in male C57BL/6 mice. Pharmacol. Rep., 2009, 61(6), 1113-1126.
457. Ni, Y.G.; Miledi, R. Blockage of 5HT2C serotonin receptors by fluoxetine (Prozac). Proc. Natl. Acad. Sci. U. S. A., 1997, 94(5), 2036-2040.
458. Thyaga, R. S.; Felten, D.L. Modulation of neuroendocrine--immune signaling by L-deprenyl and L-desmethyldeprenyl in aging and mammary cancer. Mech. Ageing Dev., 2002, 123(8), 1065-1079.
459. Thyaga, R. S.; Madden, K.S.; Stevens, S.Y.; Felten, D.L. Antitumor effect of L-deprenyl is associated with enhanced central and peripheral neurotransmission and immune reactivity in rats with carcinogen-induced mammary tumors. J. Neuroimmunol., 2000, 109(2), 95-104.
460. Flamand, V.; Zhao, H.; Peehl, D.M. Targeting monoamine oxidase A in advanced prostate cancer. J. Cancer Res. Clin. Oncol., 2010, 136(11), 1761-1771.
461. Cutolo, M.; Straub, R.H. Stress as a risk factor in the pathogenesis of rheumatoid arthritis. Neuroimmunomodulation, 2006, 13(5-6), 277-282.
462. Elenkov, I.J.; Chrousos, G.P. Stress hormones, proinflammatory and antiinflammatory cytokines, and autoimmunity. Ann. N. Y. Acad. Sci., 2002, 966, 290-303.
463. Torta, R. Depression as systemic disease: the antidepressants spectrum of actions. Psycho-Oncology, 2006, 15 (S2).
464. Elenkov, I.J.; Wilder, R.L.; Chrousos, G.P.; Vizi, E.S. The sympathetic nerve--an integrative interface between two supersystems: the brain and the immune system. Pharmacol. Rev., 2000, 52(4), 595-638.
465. Yamauchi, M.; Hiraoka, S.; Imanishi, T. Role of the serotonergic nervous system in anxiety disorders and the anxiolytic mechanism of selective serotonin reuptake inhibitors. Nihon Shinkei Seishin Yakurigaku Zasshi, 2006, 26(5-6), 193-198.